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ABSTRACT
EXPRESSION OF GENES FOR PEPTIDE/PROTEIN HORMONES AND THEIR
COGNATE RECEPTORS IN BREAST CARCINOMAS AS BIOMARKERS
PREDICTING RISK OF RECURRENCE
Michael W. Daniels
May 14, 2016
Certain hormones and/or receptors influencing normal cellular pathways
were detected in breast cancers. The hypothesis is that gene subsets predict risk
of breast carcinoma recurrence in patients with primary disease. Gene expression
of 55 hormones and 73 receptors were determined by microarray with LCMprocured carcinoma cells of 247 de-identified biopsies. Univariate and multivariate
Cox

regressions

were

determined

using

expression

levels

of

each

hormone/receptor gene, individually or as a pair. Significant genes derived for each
subset were analyzed to predict risk of cancer recurrence with 1000 LASSO
training/test sets. A 14-gene molecular signature was identified for predicting
clinical outcome without regard to estrogen or progestin receptor status of
biopsies. A three-gene signature was derived for ER+ cancers while a 9-gene
signature was deciphered for ER- cancers. Molecular signatures derived were
compared with results in public databases. Collectively, results suggest gene
subsets in primary breast cancer have been identified that predict recurrence.
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CHAPTER I
INTRODUCTION
The Surveillance, Epidemiology, and End Results (SEER) program
estimated 231,840 new breast cancer cases and 40,290 deaths in the United
States in 2015 ("Surveilance, Epidemiology, and End Results Program,"). Selfexamination to clinical examination to mammogram is a typical route to detect
breast cancer. When an area of the breast is identified as suspicious, a biopsy may
be taken to help classify a tumor as malignant. If the tumor is diagnosed as
carcinoma, then the pathologist will evaluate the lesion by stage and type. Stage
is based on several factors such as size of the cancer, number of lymph nodes
involved and signs of local invasion of the breast and metastasis to other organs
(Greenspan, Gardner, & Shoback, 1997). Some types of breast cancer may be
characterized as in situ versus invasive, ductal versus lobular and sex-hormone
receptor status (Fleisher, Dnistrian, Sturgeon, Lamerz, & Wittliff, 2002; J. Wittliff,
Pasic, & Bland, 1998). Classification of stage and grade as well as nodal status
contributes significantly to determining the prognosis and treatment of the disease.
An important consideration for assessing breast cancer prognosis and
treatment was provided by the discovery that estrogen (ER) and progestin
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receptor (PR) proteins were clinically useful biomarkers (Fisher et al., 1983; Fisher
et al., 1981; Fleisher et al., 2002; Hammond et al., 2010; James, 1984; J. Wittliff
et al., 1998). Briefly, the presence of significant levels of ER and PR in a breast
cancer biopsy was correlated with better prognosis than patients with lesion
lacking ER and PR proteins. In addition, the presence of ER and PR in a breast
cancer tissue biopsy was strongly associated with the patient’s response to
Tamoxifen, an antiestrogen-like drug that binds to ER (Fisher et al., 1983; Fisher
et al., 1981). Receptor status is now used as a combination of ER and PR with the
addition of epidermal growth factor receptor-2 (HER-2/neu) protein, which is
involved in growth regulation of cancer cells given their presence in the cell
(Fleisher et al., 2002; Hammond et al., 2010).
Common treatments for breast cancers with elevated levels of ER and PR
are the antiestrogen-like drugs (e.g., Tamoxifen, Evista/Raloxifene and
Fareston/Toremifene), which are termed SERMs (Selective Estrogen Receptor
Modulators) ("Raloxifene Hydrochloride," ; "Tamoxifen Citrate," ; "Toremifene,").
Aromatase Inhibitors such as Arimidex (Anastrozole) and Femara (Letrozole),
which block the production of estrogens from androgenic precursors produced by
the adrenal glands, are used as hormone therapies for post-menopausal patients
(Hong & Chen, 2011). HER/2 oncoprotein serves as a biomarker for treating a
patient with the drug Trastuzumab (Herceptin) which attaches itself to the HER2/neu protein that is present in the surface membranes of certain breast carcinoma
cells. For decades the Hormone Receptor Laboratory, which holds both CLIA and
Commonwealth of Kentucky licenses as a Clinical Laboratory, has determined the
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levels of these biomarkers in thousands of breast cancer tissue biopsies for
management of patients.
One area of research that is likely to improve the survival rates of women
diagnosed with breast cancer is personalized or precision medicine. Due to the
clinical and molecular heterogeneity of breast cancer, identifying genes and gene
products involved in driving the progression of the disease may provide
opportunities to design and synthesize new drugs for these new molecular targets.
In addition, knowledge of their expression in relationship to risk of breast cancer
recurrence provides additional information regarding a patient’s prognosis. Thus
research in these areas of genomics and proteomics hold promise for developing
a larger arsenal of personalized treatment options for breast cancer patients.
Expression patterns of sets of genes that accurately predict the clinical behavior
of cancers are called molecular signatures. Many genomics based signatures have
been shown effective in predicting clinical outcomes such as progression free
survival, which measures the length of time a patient lives without the appearance
of a metastasis of the disease. (Gingras, Desmedt, Ignatiadis, & Sotiriou, 2015; J.
Wittliff et al., 2002). A number of gene expression profiles (i.e., molecular
signatures) have been developed and commercialized.
It is widely documented that numerous peptide/protein hormones such as
insulin act as growth factors impacting carcinoma cell growth and may play a role
in carbohydrate metabolism during differentiation and growth of the lesion (Chen
et al., 2002; Falzon & Du, 2000). Each of the hydrophilic peptide/protein hormones
circulate freely in the blood and bring about their particular physiological actions in
3

normal target cells by associating with high affinity with their cognate receptor
proteins which are located on cell surfaces (Norman & Litwack, 1997; Pierce,
1982). Thus this diverse family of hormones which influences a wide variety of
normal cellular pathways in the many organs composing the endocrine system
when bound to their cognate receptor proteins provides a fertile and unchartered
area to explore in breast cancer. The overarching goal of this study is to determine
the relationships of the expression of the genes for each of the peptide/protein
hormones and that of their cognate receptors with clinical outcomes of breast
cancer patients. Our hypothesis is that expression profiles of subsets of these
genes may be used to predict risk of breast carcinoma recurrence in patients with
primary disease.
To the best of our knowledge, no study has analyzed collectively the gene
expression patterns of all of the peptide/protein hormones and their cognate
receptors in relationship to their association with breast cancer behavior. The
association of a peptide/protein hormone with its cognate receptor results in the
release of signaling molecules (second messengers) inside the cell to trigger a
variety of physiological changes ("Journal of receptor and signal transduction
research," 1995).
Peptide/protein hormones are produced and secreted by organs of the
endocrine system throughout our bodies affecting adjacent cells (paracrine action)
and cells located in distant organs (endocrine action). For example, insulin and
glucagon are produced by the pancreas and secreted into the bloodstream where
they influence a variety of other organs to control blood sugar levels. Surprisingly,
4

breast carcinoma cells have been found to overexpress some of these hormone
and receptor genes (Chen et al., 2002; Falzon & Du, 2000). From a variety of
previous reports addressing relationships of hormones and cancer, and my comentor’s years of experience investigating endocrine mechanisms of breast
cancer, the following questions were developed. Do certain breast carcinomas
express elevated levels of mRNA for genes of peptide/protein hormones and their
cognate receptors? Are the gene expression levels related to clinical outcomes of
the patients? Can one discern gene expression profiles (i.e., molecular signatures)
that may be useful clinically in predicting risk of breast cancer recurrence?
To begin to answer these questions we took a step-wise global approach
using the gene expression levels of 22,000 genes that had been determined by
microarray of RNA isolated from LCM-procured breast carcinoma cells (Figure 1
Flow Diagram). Determination of which peptide/protein hormones and their
cognate receptors may be playing a role in the clinical behavior of breast cancers
required surveying research literature describing the diverse family of endocrine
regulators as will be described in Chapter II. Due to the complicated nature of
analyzing multiple genes and various breast cancer subtypes, the statistical
analyses were performed in a stepwise manner as outlined in the flow diagram in
Figure 1. Each of the following Chapters (II, III and IV) describes the manner in
which the investigations were conducted, the results in the comprehensive
databases that were employed and the statistical methods used for the analyses
to identify interrelationships. These relationships are the essence of our hypothesis
that expression profiles of subsets of genes for peptide/protein hormones and their
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cognate receptors may be used to predict risk of breast carcinoma recurrence in
patients with primary disease.
In Chapter II, we evaluate univariate association of each of the identified
hormone and receptors with breast cancer progression and overall survival. The
univariate analyses in Chapter II will be extended to associations by ER/PR status.
In a similar fashion ER/PR will be evaluated in Chapters III and IV. Multivariate
analyses performed on hormone and receptor gene pairs in Chapter III explore an
exhaustive evaluation of the relationships between hormones and their cognate
receptors. Also in Chapter III, regularization techniques are employed to analyses
all 142 genes at one time. In Chapter IV, a meta-analysis was performed with
public databases to compare our results with a few highly referenced databases.
Molecular signatures close out our analyses in Chapter IV as described in the Flow
Diagram (Figure 1). The Flow Diagram is a recipe of approaches to develop
molecular signatures of clinical relevance in the future for the Hormone Receptor
Laboratory.
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Microarray Database of 22,000 Genes of Breast Cancer
Biopsies (n=247)

Chapter II
Preliminary Selection of Gene Expression
Levels for 142 Candidate Genes

Chapter III
Analyze Interaction Term
from Multivariate Cox
Regression of Peptide
Protein Hormones and
their Cognate Receptors

Chapter II
Perform Univariate Cox
Regression and Construct
Kaplan-Meier Plots for Each
Candidate Gene
Chapters II-IV
Analyze Relationship to
Conventional Biomarker
Status (ER/PR)
Chapter IV
Meta-Analyses with Public
Databases

Chapter IV
Develop Clinically Relevant Molecular Signatures of
Multiple Genes

Figure 1. Flow Diagram of Approaches and Analyses used to Decipher Clinically
Relevant Molecular Signatures
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CHAPTER II
UNIVARIATE ANALYSES
The microarray, protein biomarker and clinical follow-up databases used for
analyses described in these investigations were established by my Co-mentor, Dr.
Wittliff and collaborators almost two decades ago. (Sarah A Andres et al., 2015;
Andres, Brock, & Wittliff, 2013; Andres, Edwards, & Wittliff, 2012; Andres & Wittliff,
2011, 2012; Kerr II & Wittliff, 2011; Kidd et al., 2010; Kruer, Cummins, Powell, &
Wittliff, 2013; Ma et al., 2003; Tecimer et al., 2000; J. Wittliff et al., 1998; J. L.
Wittliff, 2010) Briefly, intact frozen tissue sections of de-identified human breast
carcinoma tissue biopsies as well as those that were processed for a sophisticated
technique called Laser Capture Microdissection (LCM) for the microarray analyses
allowed collection of specific cell types in a non-destructive manner. (Andres &
Wittliff, 2011, 2012) The results collected from microarray of LCM-procured cells
are truly unique in that only the expressions of carcinoma cell genes were
determined. This database was complemented by results in other comprehensive
databases that contained quantitative results of protein biomarker levels (ER, PR
and HER-2) that are used routinely in clinical management of breast cancer, qPCR
validated expression levels of almost 100 genes as well as extensive results on
the features of the carcinoma biopsy and numerous patient parameters including
clinical outcomes.
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Methods and Materials
Microarray Database
Using an IRB-approved biorepository and associated databases composed
of tissue specimens previously collected by Dr. Wittliff’s laboratory (CLIA and
Commonwealth of Kentucky licensed) at the University of Louisville for clinical
assays of estrogen (ER) and progestin receptors (PR), de-identified tissue
specimens of primary breast cancers obtained from 1988 - 1996 were examined
using REMARK criteria (McShane et al., 2006) as described in previous studies.
(Sarah A Andres et al., 2015; Andres et al., 2013; Andres & Wittliff, 2011; Kerr II &
Wittliff, 2011; Kruer et al., 2013) Patients were treated with the standard of care at
the time of diagnosis. Tissue-based properties (e.g., pathology, grade, size, and
tumor marker expression) and patient-related characteristics (e.g., age, race,
smoking status, menopausal status, stage, and nodal status) were utilized to
determine relationships between gene expression and clinical parameters.
Microarray analyses were performed on LCM procured carcinoma cells from 247
breast cancer tissue biopsies as described. (Ma et al., 2003; J. L. Wittliff, 2010)
Figure 2 describes the characteristics of the patient analyzed in the microarray
database.
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Patient Characteristics
Median Age (range)
59 years (21-89.5)
Median Observation Time (range)
65 months (3-155)
Race
White
Black
Other
Histology
Invasive ductal carcinoma
Lobular carcinoma
Medullary carcinoma
Other/Unknown
Median Tumor Size (range)
27 mm (3-100)
Stage
0
1
2A
2B
3A
3B
4
Unknown
Grade
1
2
3
4
Unknown
Estrogen Receptor Status
Negative
Positive
Lymph Node Status
Negative
Positive
Unknown
Recurrence Status
Yes
No
Never disease-free

n
247
247
211
34
2
193
15
8
31
218
3
60
85
55
22
13
4
5
14
70
94
1
68
98
151
125
102
20
98
146
3

Table 1. Summary of Patient Characteristics in Microarray Database
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Gene Expression Analyses
Levels of mRNA expression were analyzed by microarray and qPCR
according to the protocols described in publications of previous investigators with
Dr. Wittliff after isolation and the quality of RNA was evaluated with Agilent RNA
6000 Nano Kits and the BioanalyzerTM Instrument (Agilent Technologies, Palo Alto,
CA) (Sarah A Andres et al., 2015; Andres et al., 2013; Andres & Wittliff, 2011,
2012; Kerr II & Wittliff, 2011). Relative gene expression levels were determined
from qPCR with the ΔΔCt method using ACTB for normalization and Universal
Human Reference RNA (Stratagene, La Jolla, CA) as the calibrator.
Preliminary Gene Selection
An exhaustive inquiry of prevalent literature revealed 63 peptide/protein
hormones and 82 cognate receptor proteins as shown in the second box of Figure
1 flow diagram. (Greenspan et al., 1997; Norman & Litwack, 1997) There are a
number of peptide/protein hormones that have been reported to associate with
multiple receptor proteins. For example, somatostatin (SST) is known to bind with
five receptor isoforms – somatostatin receptor 1 (SSTR1), somatostatin receptor 2
(SSTR2), somatostatin receptor 3 (SSTR3), somatostatin receptor 4 (SSTR4) and
somatostatin receptor 5 (SSTR5). (Hoyer et al., 1995) Similarly, receptors may pair
with more than a single peptide/protein hormone. For instance, Spier and de Lecea
(2000) demonstrated that another hormone, cortistatin (CORT), was also
recognized by each of the five somatostatin receptors described above. Among
the extensive repository of expression levels for ~22,000 genes in our microarray
results of LCM-procured carcinoma cells, those genes for 61 hormones and 81
11

receptors were identified as candidates for analyses. The 247 tissue biopsies from
patients with primary invasive ductal carcinoma served as the principal study
population.
Univariate Cox Regression
Univariate Cox regression was performed on each of the 142 gene
candidates using their relative expression levels as described in the third step of
the flow diagram (Figure 1). Both Progression Free Survival (PFS) and Over-All
Survival (OS) were analyzed as clinical outcomes for each gene. Univariate Cox
models employed relative gene expression values as a single covariate (i.e., SST)
and investigated the extent to which expression levels of a single gene in the cohort
predicted the risk of recurrence of breast cancer (PFS) or succumbing to that
disease (OS).
The general formula for the hazard function of a Cox proportional hazard
model is as follows: ℎ(𝑡) = ℎ0 (𝑡) exp(𝛽1 𝑥1 + 𝛽2 𝑥2 + ⋯ + 𝛽𝑝 𝑥𝑝 ). (Bradburn, Clark,
Love, & Altman, 2003) The hazard function (ℎ(𝑡)) is time dependent, which
changes over time along with the baseline hazard (ℎ0 (𝑡)). The baseline hazard
measures the risk when all covariates (𝑥1 , 𝑥2 … 𝑥𝑝 ) are equal to 0. Although the
baseline hazard may change over time, one of the assumptions for Cox models is
that the hazard for different subsets of the population will be proportional to the
baseline hazard at all times. The beta coefficients (𝛽1, 𝛽2 … 𝛽𝑝 ), which link the
covariates to the hazard at time t, are determined by maximizing the partial
likelihood function associated with the model. Covariates are variables such as
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relative gene expression values for each of the hormones or their receptors.
Univariate Cox regressions have a single beta coefficient calculated for a single
covariate as shown here: ℎ(𝑡) = ℎ0 (𝑡) exp(𝛽1 𝑥1 ).
Hazard ratios (HR) were derived from univariate Cox regression models by
the exponentiation of 𝛽1 and calculated for each of the 142 candidate genes. A
hazard ratio for these models compares hazards (or risks for the clinical outcome
being measured) at two different levels of gene expression. (Klein &
Moeschberger, 2003) Since relative gene expression values are continuous
covariates, the HR compares the hazard at any relative gene expression value to
the hazard at a one unit level increase in relative gene expression.

𝐻𝑅 =

ℎ0 (𝑡) exp(𝛽1 (𝑥1 + 1))
= exp(𝛽1 )
ℎ0 (𝑡) exp(𝛽1 𝑥1 )

An HR of greater than one represents an increase in risk, whereas a value of less
than one represents a decrease in risk. An HR equal to one represents no
difference in risk.
Each of the statistical computations was performed with R version 3.2.3.
The commands coxph and cox.zph in the R package survival (Therneau, 2013)
were used to calculate all univariate and multivariate Cox regressions and to
validate the assumption of proportionality in significant genes. Cox regression pvalues were adjusted for multiple comparisons using the Benjamini & Hochberg
method (Benjamini & Hochberg, 1995) with 0.30 “discovery” cutoff. Relative gene
expression levels determined with LCM- procured carcinoma cells from 247
patients were divided into groups expressing values that were above and below
13

the median for each gene candidate. These two groups of results were analyzed
in Kaplan-Meier (KM) plots using the commands plot and survfit. The survdiff
command performed a log-rank test comparing survival times between the two
groups.
Influence of Estrogen Receptor (ER) and Progestin Receptor (PR) Status on Gene
Expression Levels
Measurements of the protein biomarkers, ER and PR, have significant
importance in predicting clinical outcomes of breast cancer patients such as risk
of recurrence and over-all survival. (Fisher et al., 1987; Fisher et al., 1983; Fisher
et al., 1981; Fleisher et al., 2002; Hammond et al., 2010; J. Wittliff et al., 1998) For
example, patients with breast cancers exhibiting both ER and PR are reported to
have a better prognosis and are candidates for anti-hormone therapy compared to
those with ER and PR negative breast cancers. (Fisher et al., 1987; Fisher et al.,
2001; Fisher et al., 1981) This is thought to be due in part, to the observation that
ER, when complexed with its native ligand, estradiol-17 B or an estrogen mimic
(e.g., Tamoxifen), stimulates the production of PR. (Cormier, Wolf, & Jordan, 1989)
Comprehensive clinical trials of breast cancer patients treated with Tamoxifen,
such as those of the NSABP support this conclusion. (Fisher et al., 1987; Fisher
et al., 1983; Fisher et al., 1981)
Patients were categorized into the breast cancer subsets based on the ER
and PR protein status of the tissue biopsy. Patients were also stratified according
to carcinoma cells exhibiting one of the four combinations of the two protein
biomarkers, either ER+/PR+, ER+/PR-, ER-/PR+ or ER-/PR-. Univariate Cox
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regression was first performed for patients with cancers stratified by each protein
status, ER+, ER-, PR+ and PR-. Then patients were evaluated according to one
of the four possible combinations of ER and PR (e.g., ER+/PR+, ER+/PR-, ER/PR+ or ER-/PR-) exhibited by their carcinoma cells with each of the 142 gene
candidates. Kaplan-Meier plots were constructed for each gene using the various
subsets of ER and PR. Box plots were constructed according to receptor status for
each of the 142 candidate genes using the R command boxplot. The boxplots
displayed the relative gene expression in the LCM-procured carcinoma cells for
patients bifurcated by ER and PR status. The null hypotheses that the two groups
come from identical populations was tested using the R command wilcox.test. The
R command employed an unpaired independent two-sample Mann-WhitleyWilcoxon test by comparing ER+ to ER- groups and PR+ to PR- groups of breast
cancers.
Results
Univariate Cox Regression of PFS and OS without Regard to ER and PR Status
From univariate Cox regression for PFS, expression levels of fifteen genes
for peptide/protein hormones and nineteen receptors showed significance at the
adjusted p-value of <0.30 (Table 2). Noteworthy among the findings, the
expression of POMC, whose mRNA transcript is quite large containing the
sequences for a number of hormones, exhibited the highest statistical significance.
(Lee et al., 2006) POMC had a HR of 1.72, which can be interpreted as patients
with breast carcinomas expressing this gene at one unit higher have a 72%
increase in risk of recurrence of metastatic breast cancer. The results obtained for
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SST and SSTR1 are of particular interest because they are a hormone-cognate
receptor pair, which appeared among the top five genes for univariate Cox
regression for PFS.
From univariate Cox regression for OS, expression levels of seven genes
for peptide/protein hormones and ten receptor genes showed significance at the
adjusted p-value of <0.30 (Table 3). Interestingly, expression of POMC gene
related to breast cancer OS mirrored the highest statistical significance observed
when PFS was calculated. All seventeen significant genes related to OS exhibited
significant relationships with PFS. Also, the hormone-receptor pair POMC and
MC5R exhibited statistical significance individually for univariate Cox regression
for OS.
Univariate Cox Regression of PFS and OS According to ER Status
Using gene expression levels from 146 ER+ breast cancer carcinomas,
univariate Cox regression determined that two peptide/protein hormones, SST and
renin (REN), exhibited significant mRNA expression levels related to PFS and one
receptor (SSTR2) was related to OS (Table 4). SST reappeared as significant for
predicting PFS as it did for predicting PFS without regards to hormone receptor
status. SSTR2, a cognate receptor for SST, exhibited significance for OS and will
reappear in our molecular signature for ER+ breast cancers. Also showing
significance for PFS is REN, which is normally produced in the kidneys when
intrarenal blood pressure drops. The inhibition of REN has been demonstrated to
mitigate angiogenesis, the production of new blood vessels. (Rodrigues-Ferreira
& Nahmias, 2015). Cancer cells need more blood supply to provide them with the
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nutrients to grow faster. The HR of REN is 2.93 meaning that cancers with higher
levels of expression of REN are more likely to have a shorter time to progression.
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Gene Symbol
POMC
CALCR
SST
IGF1R.clone
SSTR1
TMSB15A
PPY
CRH
SSTR3
REN
TMSB10
ACVR2B
ACVR2A
PRL
VIPR1
NPY1R
SCT
NPY6R
INSR.AL365454
ACVR1
ACVR1B
RLN1
RXFP3
MC5R
GHR
AVPR2
PTH
EDN1
GHSR
RLN2
AGTRAP
VIPR2
AVPR1A
GAL

β
0.54
0.44
0.55
-0.17
0.65
0.14
0.93
0.55
0.97
0.61
0.4
0.35
0.29
0.32
-0.26
-0.16
0.58
-0.99
-0.25
-0.27
0.25
-0.21
1.2
0.6
0.4
0.75
-1.28
0.37
-1.07
-0.13
-0.31
-0.1
0.88
0.11

HR
1.72
1.56
1.73
0.84
1.91
1.16
2.55
1.73
2.64
1.85
1.49
1.42
1.34
1.38
0.77
0.85
1.79
0.37
0.78
0.76
1.29
0.81
3.32
1.83
1.5
2.11
0.28
1.45
0.34
0.88
0.73
0.91
2.41
1.12

95% CI (HR)
(1.37,2.15)
(1.21,2.01)
(1.27,2.35)
(0.76,0.94)
(1.28,2.84)
(1.05,1.27)
(1.32,4.92)
(1.18,2.54)
(1.28,5.46)
(1.16,2.93)
(1.1,2.02)
(1.08,1.86)
(1.06,1.7)
(1.06,1.79)
(0.62,0.96)
(0.74,0.98)
(1.08,2.97)
(0.15,0.9)
(0.61,0.99)
(0.58,1)
(1.01,1.65)
(0.66,0.99)
(1.07,10.27)
(1.02,3.29)
(1.02,2.2)
(1.04,4.28)
(0.08,0.98)
(1.03,2.05)
(0.13,0.94)
(0.77,1)
(0.53,1.01)
(0.82,1)
(0.95,6.11)
(0.99,1.26)

adj. p
<0.001
0.03
0.03
0.05
0.05
0.07
0.10
0.10
0.13
0.13
0.13
0.14
0.16
0.16
0.18
0.21
0.21
0.22
0.23
0.23
0.23
0.23
0.23
0.23
0.23
0.23
0.23
0.23
0.23
0.23
0.27
0.27
0.28
0.30

Table 2. Summary of Genes with Expression Levels Associated with PFS. As described
in Methods and Materials, expression levels of the 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.
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Gene Symbol
POMC
CALCR
TMSB15A
IGF1R.clone
SSTR3
SCT
NPY6R
TMSB10
ACVR2A
PPY
PTH
NPY1R
MC5R
VIPR1
VIPR2
EDN1
GHSR

β
0.52
0.45
0.18
-0.17
1.1
0.79
-1.36
0.45
0.35
0.87
-1.77
-0.2
0.72
-0.27
-0.13
0.44
-1.34

HR
1.68
1.57
1.19
0.85
3.01
2.21
0.26
1.57
1.42
2.38
0.17
0.82
2.06
0.76
0.88
1.56
0.26

95% CI (HR)
(1.34,2.1)
(1.19,2.08)
(1.07,1.33)
(0.75,0.96)
(1.34,6.76)
(1.27,3.83)
(0.09,0.71)
(1.12,2.2)
(1.08,1.86)
(1.15,4.93)
(0.04,0.77)
(0.69,0.97)
(1.07,3.97)
(0.59,0.98)
(0.78,0.99)
(1.05,2.3)
(0.08,0.87)

adj. p
<0.001
0.08
0.08
0.16
0.16
0.16
0.16
0.16
0.19
0.26
0.26
0.26
0.28
0.28
0.28
0.28
0.28

Table 3. Summary of Genes with Expression Levels Associated with OS. As described in
Methods and Materials, expression levels of the 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.

Using gene expression levels from 101 ER- breast cancer carcinomas,
univariate Cox regression determined that mRNA levels of four genes for
peptide/protein hormones and two receptor genes were correlated with a
significant for predicting PFS and four genes for peptide/protein hormones
predicted OS (Table 5). The gene expression levels of POMC were significant for
predicting PFS and OS for ER- cancers similarly to our observation for predicting
PFS and OS without regard to receptor status. CALCR, POMC, GH1 and PRL
were significant for PFS and will reappear in our molecular signature for ERcancers. Growth hormone (GH1) is typically produced in the pituitary gland
19

regulated by GHRH and SST from the hypothalamus. Models with SST and GHRH
could be performed in future studies to see if the cancer cells may be controlling
levels of GH1 by autocrine means.
Univariate Cox Regression of PFS and OS according to PR status
Using gene expression levels from 151 PR+ breast cancer carcinomas,
univariate Cox regression determined that one peptide/protein hormone, thymosin
β10 (TMSB10), exhibited significance for predicting PFS and three peptide/protein
hormones, CALCA, TMSB10 and POMC, were significant for predicting OS (Table
6). TMSB10 was first discovered in the thymus but is made throughout the body.
TMSB10 has been shown to be overexpressed in lung and pancreatic cancer and
even targeted for therapy. (Alldinger et al., 2005; Langevin, Kratzke, & Kelsey,
2015) Are the mechanisms that cause TMSB10 to be overexpressed in lung and
pancreatic cancers somehow related to breast cancers that exhibit high levels of
PR but not necessarily ER? Interestingly, POMC is significant for OS but not PFS
in a sex hormone positive (PR+) subtype. Could early deaths from patients who
are ER- but PR+ be driving the significance for POMC?
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A. PFS ER+
Gene Symbol
SST
REN

β
0.73
1.08

HR
2.08
2.93

95% CI (HR)
(1.28,3.39)
(1.47,5.85)

adj. p
0.23
0.23

B. OS ER+
Gene Symbol
SSTR2

β
0.28

HR
1.32

95% CI (HR)
(1.11,1.57)

adj. p
0.27

Table 4. Summary of Genes with Expression Levels Correlating either with PFS (A) or
OS (B) for 146 ER+ Breast Carcinomas. As described in Methods and Materials,
expression levels of 142 candidate genes were determined using LCM-procured cells
from 247 breast cancer biopsies.

A. PFS ERGene Symbol
CALCR
POMC
GH1
PRL
AVPR1A
SCT

β
0.43
0.4
-0.76
0.58
1.83
0.8

HR
1.53
1.49
0.47
1.79
6.23
2.24

95% CI (HR)
(1.15,2.04)
(1.17,1.9)
(0.28,0.79)
(1.18,2.71)
(1.81,21.4)
(1.19,4.2)

adj. p
0.16
0.16
0.16
0.16
0.16
0.29

B. OS ERGene Symbol
POMC
GH1
PRL
SCT

β
0.37
-0.84
0.54
0.94

HR
1.45
0.43
1.72
2.55

95% CI (HR)
(1.13,1.87)
(0.24,0.79)
(1.15,2.56)
(1.33,4.88)

adj. p
0.28
0.28
0.28
0.28

Table 5. Summary of Genes with Expression Levels Correlating either with PFS (A) or
OS (B) for 101 ER- Breast Carcinomas. As described in Methods and Materials,
expression levels of 142 candidate genes were determined using LCM-procured cells
from 247 breast cancer biopsies.
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A. PFS PR+
Gene Symbol
TMSB10

β
0.97

HR
2.63

95% CI (HR)
(1.56,4.44)

adj. p
0.04

B. OS PR+
Gene Symbol
CALCA
TMSB10
POMC

β
0.38
0.87
0.86

HR
1.46
2.39
2.36

95% CI (HR)
(1.14,1.85)
(1.34,4.27)
(1.29,4.34)

adj. p
0.23
0.23
0.27

Table 6. Summary of Genes with Expression Levels Associated either with PFS (A) or
OS (B) for 151 PR+ Breast Carcinomas. As described in Methods and Materials,
expression levels of 142 candidate genes were determined using LCM-procured cells
from 247 breast cancer biopsies.
Using gene expression levels from 96 PR- breast cancer carcinomas,
univariate Cox regression determined that five genes for peptide/protein hormones
and five receptor genes were significant for predicting PFS. No genes were found
to be significant after adjusting p-values for multiple comparisons (Table 7).
CALCR, POMC and PRL are shown to have an association with PFS for PRbreast cancer carcinomas and were also associated with ER- breast cancer
carcinomas. These three genes will be common to two molecular signatures. Since
1995, researchers have known about the ability of breast cancer cells to secrete
active forms prolactin (PRL) possibly through autocrine mechanisms, although
paracrine mechanisms could not be ruled out. (Ginsburg & Vonderhaar, 1995) We
will look at the relationship between PRL and its cognate receptor PRLR in Chapter
Three but further study could be performed on the statistical interactions of PRL
with other hormones and receptors.
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PFS PRGene Symbol
CALCR
POMC
SST
SSTR1
CRH
AVPR2
AVPR1A
ACVR1
PRL
PTH

β
0.56
0.43
0.71
0.67
0.62
1.18
1.74
-0.4
0.42
-2.31

HR
1.75
1.54
2.03
1.96
1.86
3.25
5.71
0.67
1.52
0.1

95% CI (HR)
(1.3,2.37)
(1.18,2.01)
(1.26,3.26)
(1.23,3.13)
(1.21,2.87)
(1.39,7.57)
(1.51,21.57)
(0.48,0.93)
(1.07,2.16)
(0.01,0.71)

adj. p
0.04
0.11
0.14
0.14
0.14
0.15
0.20
0.30
0.30
0.30

Table 7. Summary of Genes with Expression Levels Associated with PFS for 96 PRBreast Carcinomas. As described in Methods and Materials, expression levels of 142
candidate genes were determined using LCM-procured cells from 247 breast cancer
biopsies.

Univariate Cox Regression of PFS and OS according to ER/PR status
Since both the status of ER and PR are considered in the clinical setting
when assessing a patient’s risk of recurrence and selection of a therapeutic agent,
these studies utilized the results of clinical determinations of the steroid hormone
receptors. (Fisher et al., 1987; Fisher et al., 1983; Fisher et al., 1981; Fleisher et
al., 2002; Hammond et al., 2010; J. Wittliff et al., 1998) The analyses described
include the four combinations ER+/PR+, ER+/PR-, ER-/PR+ and ER-/PR- status
of each of the breast cancer surgical biopsies submitted for ER and PR protein
analyses. In general, a patient with a breast carcinoma determined to be ER+/PR+
exhibits the best prognosis compared to the patients with cancers exhibiting the
other combinations. Best prognosis implies that the patient is expected to have a
lower risk of breast cancer recurrence compared with patients with cancer biopsies
exhibiting the other three combinations of ER and PR. A patient with ER-/PR23

breast carcinoma exhibits the worst prognosis compared to that the other patients.
In addition, patients with ER-/PR- tumors are not candidates for hormone-receptor
protein based therapies such as tamoxifen. (Fisher et al., 1987; Hammond et al.,
2010; Kerr II & Wittliff, 2011)
Since our goal is to decipher molecular signature for predicting breast
cancer outcomes, we undertook the following analyses. Using gene expression
levels from 118 ER+/PR+ breast cancer carcinomas, univariate Cox regression
determined that the receptor SSTR2 exhibited significance for predicting OS
(Table 8). Using gene expression levels determined from LCM-procured of 28
ER+/PR- breast cancer carcinomas, univariate Cox regression determined that
one peptide/protein hormone, EPO, and two genes of receptors, CALCR and
ACVR1B, had significance for predicting PFS (Table 9). However since this sample
group only contained 28 patients, caution must be taken in the interpretation of
these analyses. We noted that erythropoietin, EPO had not appeared in any of the
gene subsets detected thus far. Furthermore CALCR has been significant for
predicting PFS of ER+/PR-, PR-, ER- breast cancer patients and for predicting
PFS and OS without regard to receptor status.
The expression of ER-/PR+ protein biomarkers in a breast cancer is
infrequently observed and since the action of ER is known to provoke the
production of PR, its appearance is the focus of research. (Andres & Wittliff, 2012;
Fleisher et al., 2002; J. Wittliff et al., 1998) Unfortunately, using gene expression
levels from 33 ER-/PR+ breast cancer carcinomas, univariate Cox regression
determined no genes of significance after adjusting p-values for multiple
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comparisons. This may be due to a small sample size. A few significant findings
from unadjusted p-values could have been novel in their implications.
Breast carcinoma biopsies that lack both ER and PR protein (ER-/PR-) are
widely known to correlate with poor prognosis of breast cancer patients and their
lack of response to anti-hormone therapies. (Andres & Wittliff, 2012; Fleisher et
al., 2002; J. Wittliff et al., 1998) Using gene expression levels determined by
microarray from LCM-procured carcinoma cells of 68 ER-/PR- breast cancer
carcinomas, univariate Cox regression determined mRNA expression levels of two
peptide/protein hormones, POMC and PRL, significant for predicting PFS (Table
10). The genes for PRL and POMC appear later in our molecular signature for ERbreast carcinomas.
Analyses of Clinical Relevance using Kaplan-Meier Plots
Due to the numerous genes exhibiting significance for predicting PFS and
OS of breast cancer for each category of receptor status, a representative sample
of Kaplan-Meier plots has been presented. (Rich et al., 2010) Without regards to
ER/PR status, IGF1R.clone and GAL genes showed significant differentiation for
predicting PFS and OS between cancers that expressed the gene above the
median versus compared to those that expressed the gene below the median. The
median is taken as a first discriminator in this thesis, however later analyses for
the development of manuscripts will also derive outcomes as a function of
quartiles. TMSB10 expression was significant for predicting PFS while that of
activin A receptor type IIA, ACVR2A, was significant for predicting OS. The risk of
recurrence and survivorship was worse for patients whose tumors expressed
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IGF1R.clone mRNA below the median and GAL, TMSB10 and ACVR2A mRNA
expression levels that were above the median.
For ER+ cancers, SST gene expression showed a significant differentiation
for predicting PFS and a poor prognosis for patients whose lesions expressed the
gene above the median. SSTR2 was significant for predicting OS with a poor
prognosis for patients whose tumors expressed the gene above the median. For
ER- carcinomas, expression of growth hormone, GH1, predicted both PFS and OS
that was highly statistically significant with a poor prognosis for those whose breast
cancers expressed GH1 below the median.
For PR+ cancers, glycoprotein hormone alpha polypeptide, CGA, showed
a significant differentiation for predicting PFS while that of endothelin, EDN1,
showed significance for predicting OS using Kaplan-Meier plots.

Patients

expressing CGA and EDN1 above the median were correlated with a worse
prognosis compared to patients expressing these genes at levels below the
median. For PR- cancers, arginine vasopressin receptor 2, AVPR2, significantly
differentiated patients above and below the median for PFS and GH1 significantly
differentiated patients above and below the median for OS. Patients with breast
cancers expressing CGA above the median and patients with breast cancers
expressing GH1 below the median had a worse prognosis.
Examination of ER+/PR+ carcinomas revealed that CALCA significantly
differentiated patient outcome for PFS while SSTR2 showed significance for
predicting OS. Patients expressing CALCA and SSTR2 above the median were
correlated with a worse prognosis than those with gene expression levels below
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the median. The most significant findings from the Kaplan-Meier plots were
revealed in carcinoma cells classified as ER-/PR-, the biomarker status that is
related to the worse prognosis among the four combinations. When ER-/PRcancers were examined, GH1 expression was highly significant for predicting PFS
and OS with those whose lesions expressed GH1 below the median having the
highest risk of recurrence and survivorship.
Evaluation of Influence of Steroid Hormone Receptor Status using Boxplots
One of the goals of this study was to determine if there were candidate
genes whose expression was related to the expression levels of either ER or PR
protein. Such relationships would suggest that steroid hormone action may be
related to the expression of certain peptide/protein hormone genes and the genes
for their receptors. Due to the magnitude of the analyses and results for the 142
candidate genes only representative boxplots that showed the greatest statistical
significance are displayed. Considering influence of ER, the relative gene
expression of receptor activity modifying protein 2 (RAMP2), IGF1R, IGF1R.clone,
angiotensin II receptor, type 1 (AGTR1) and thyrotropin-releasing hormone (TRH)
were significantly higher levels in ER+ carcinoma cells compared to their ERcounterparts. The relative gene expression of ACVR2A and GAL in ER- cancers
was significantly higher than observed in ER+ cancer cells. The relative gene
expression of AGTR1 and IGF1R.clone in PR+ breast cancers was expressed at
a significantly higher level than their expression levels in PR- carcinoma cells. A
boxplot (results not shown) revealed that GH1 expression was significant for both
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ER and PR. GH1 was overexpressed in ER- and PR- subgroups compared to ER+
and PR+ carcinomas.

OS ER+/PR+
Gene Symbol
SSTR2

β
0.34

HR
1.4

95% CI (HR)
(1.14,1.72)

adj. p
0.16

Table 8. Summary of Genes with Expression Levels Associated with OS for 118
ER+/PR+ Breast Carcinomas. As described in Methods and Materials, expression levels
of 142 candidate genes were determined using LCM-procured cells from 247 breast
cancer biopsies.

PFS ER+/PRGene Symbol
CALCR
ACVR1B
EPO

β
1.11
1.16
0.61

HR
3.03
3.2
1.85

95% CI (HR)
(1.46,6.29)
(1.48,6.95)
(1.25,2.74)

adj. p
0.15
0.15
0.15

Table 9. Summary of Genes with Expression Levels Associated with PFS for 28 ER+/PRBreast Carcinomas. As described in Methods and Materials, expression levels of 142
candidate genes were determined using LCM-procured cells from 247 breast cancer
biopsies.

PFS ER-/PRGene Symbol
POMC
PRL

β
0.4
0.63

HR
1.49
1.88

95% CI (HR)
(1.14,1.94)
(1.23,2.86)

adj. p
0.25
0.25

Table 10. Summary of Genes with Expression Levels Associated with PFS for 68 ER/PR- Breast Carcinomas. As described in Methods and Materials, expression levels of
142 candidate genes were determined using LCM-procured cells from 247 breast
cancer biopsies.
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Figure 2 Representative Kaplan-Meier Plots Comparing Above and Below the Median
Relative Gene Expression (1). Without regards toward receptor status, IGF1R.clone (A),
TMSB10 (B) and GAL (C) displayed significance difference between groups for PFS, while
IGF1R.clone (D), ACVR2A (E) and GAL (F) were significant for OS. For ER+ tumors, SST (G)
displayed significance difference between groups for PFS, while SSTR2 (H) was
significant for OS. For ER- tumors, GH1 (I) displayed significance difference between
groups for PFS.
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Figure 3. Representative Kaplan-Meier Plots Comparing Above and Below the Median
Relative Gene Expression (2). For ER- tumors, GH1 (A) displayed significance difference
between groups for OS. For PR+ tumors, CGA (B) displayed significance difference
between groups for PFS, while EDN1 (C) was significant for OS. For PR- tumors, AVPR2
(D) displayed significance difference between groups for PFS, while GH1 (E) was
significant for OS. For ER+/PR+ tumors, CALCA (F) displayed significance difference
between groups for PFS, while SSTR2 (G) was significant for OS. For ER-/PR- tumors, GH1
(H) displayed significance difference between groups for both PFS and OS.
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Figure 4. Representative Boxplots Comparing Distributions of Relative Gene Expressions
by Receptor Status. The gene expression of RAMP2 (A), IGF1R (B), IGF1R.clone (C),
AGTR1 (D) and TRH (E) in ER+ tumors was expressed at a significantly higher level than
ER- tumors. The gene expression of ACVR2A (F) and GAL (G) in ER- tumors was
expressed at a significantly higher level than ER+ tumors. The gene expression of AGTR1
(H) and IGF1R.clone (I) in PR+ tumors was expressed at a significantly higher level than
PR- tumors.
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Discussion
The use of these comprehensive, de-identified databases containing a
variety of molecular biological results complemented by characteristics of the
breast carcinoma and the clinical outcome of the patient have allowed the
exploration of original questions and hypotheses related to biomarkers of clinical
relevance in breast carcinoma management. These matchless resources
combined with a range of statistical tests, bioinformatics tools and novel,
sophisticated software have given me a unique opportunity to learn new
approaches and integrate results of complex molecular assays with clinical
outcomes. As a result, we have uncovered a gold mine of potential
interrelationships between gene expression/ protein biomarker levels and breast
carcinoma behavior.
In support of our approach outlined in Figure 1 (Flow Diagram), the integrity
of the databases mined in these investigations is based on the following facts.
Firstly, each of the tissue biopsies of breast cancer was collected in Pathology
Departments of hospitals utilizing standardized protocols for specimen handling
developed by Dr. Wittliff and then processed and stored deep frozen under
stringent conditions established in the Hormone Receptor Laboratory. The HRL
holds both CLIA and Commonwealth of Kentucky licenses as a clinical laboratory.
Secondly, each of the specimens in the Biorepository and results
accumulated in the comprehensive databases were de-identified under approval
of the Institutional Review Board (IRB) of the University of Louisville. Next, using
these frozen biopsy specimens, tissue sections were uniformly processed and only
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breast carcinoma cells were Laser Capture Microdissected in a non-destructive
fashion using protocols established by Dr. Wittliff and collaborators. (J. L. Wittliff,
2010) The extraction and purification of RNA from LCM-procured cells as well as
RNA amplification and microarray analyses of gene expression were performed in
well controlled, highly reproducible assays. This is documented by acceptance of
various publications (Andres et al., 2013; Metzler et al., 2015; J. L. Wittliff, 2010)
as well as acceptance of patent applications filed describing molecular profiling of
breast cancers (JLW & Arcturus patent applications).
Lastly, microarray results of expression of certain genes were validated by
qPCR (Andres & Wittliff, 2011, 2012; Kerr II & Wittliff, 2011) and determinations of
ER and PR protein levels in tissue biopsies were performed with FDA-approved
kits that gave quantitative results. My Co-mentor, Dr. Wittliff developed the radio
ligand-binding assays which not only measured the levels of the active ER and PR
proteins but gave affinities of the association of the sex hormone receptors for their
ligands which were radioactively labeled. Thus the databases and statistical
approaches that I have used to investigate expression of genes for 142
peptide/protein hormone and their receptor proteins in breast carcinoma cells to
derive clinically useful molecular signatures have great reliability.
POMC was the most significant gene for univariate Cox regression without
regard to receptor status. POMC is a 241 amino acid long polypeptide typically
produced in the pituitary gland and is cleaved at various sites to make a number
of other proteins including adrenocorticotropic hormone (ACTH) and β-lipotropin.
(Kaushal & Sinha, 2015) POMC is secreted in response to corticotropin-releasing
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hormone (CRH), a gene also significant for univariate Cox regression. ACTH is
necessary for steroidogenesis, which converts cholesterol into steroids such as
progesterone, estrogen and cortisol (an immunosuppressant). (Hanukoglu, 1992)
The gene pairs POMC & MC5R, SST & SSTR1, SST & SSTR3, RLN1 & RXFP3
and RLN2 & RXFP3 had both genes individually among the univariate significant
genes.
Twelve of the 34 genes significant for univariate Cox regression for PFS
without regard to receptor status were also significant for the log-rank test derived
for Kaplan-Meier plots. Of the twelve genes showing significance for univariate
Cox regression and Kaplan-Meier plots, POMC, VIPR1, RLN1, ACVR2A, SST and
CALCR will be in the 14-gene signature for predicting PFS as described in the flow
diagram. (Figure 1)
Nearly half the genes (67 of 142) had significantly different relative gene
expressions for either ER+ versus ER- or PR+ versus PR- as shown by a
representative sample of boxplots. An important question for these 67 genes is
whether estrogen or progesterone is regulating them. The Kaplan-Meier plots
without regards to receptor status provide some evidence for this question. Among
the 22 significant genes for PFS or OS for Kaplan-Meier plots, thirteen are common
to those significant for differences between ER and PR status expressed in the
boxplots. The common genes are IGF1R.clone, AGTRAP, ACVR2A, RLN1, TRH,
POMC, GH1, VIPR1, EDN1, GAL, GHSR, TMSB10 and TMSB15A. These genes
are associated with the signaling pathways for estrogen or progesterone and
require further investigation to discern the association.
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Growth hormone (GH1), POMC and CALCR were highly significant for
univariate Cox regression and Kaplan-Meier plots for ER- breast carcinomas and
will be in the 9-gene signature for ER- cancers as described in the flow diagram.
(Figure 1) Interestingly, the only gene that showed a protective effect as relative
gene expression increases (negative beta coefficient) for PFS was GH1. GH1 is
secreted in the pituitary gland and up regulated by growth hormone releasing
hormone (GHRH) and down regulated by somatostatin in the hypothalamus.
(Wagner et al., 2006) GH1 promotes insulin-like growth factor (IGF1) in the liver.
IGF1 has been targeted in a pathway to regulate the metastasis of breast cancer.
(Sachdev, 2008; Yang & Yee, 2012) There was no surprise to find IGF1 eventually
show up in our 9-gene model for ER- breast cancers. Why does the increase in
the expression of a gene, which promotes a gene in a known breast cancer
metastasis pathway, has a protective effect against the progression of breast
cancer?
Clinically, cancers identified as ER-/PR- have the worst prognosis. Prolactin
(PRL) was the most significant gene for PFS and OS for these cancers followed
closely by GH1, POMC and CALCR, mentioned above for ER- cancers. Elevated
circulating PRL has been shown to increase the risk of breast cancer in situ. (Tikk
et al., 2015) PRL and prolactin receptor will appear in our 9-gene molecular
signature for ER- breast cancers. Before modeling any molecular signatures, we
need to evaluate how these hormones and receptors may be affecting one another
statistically. Collectively, these results lead us to look at various models and
statistical techniques for multivariate analyses.
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CHAPTER III
MULTIVARIATE ANALYSES
The analyses described in Chapter One using gene expression levels from
LCM-procure breast carcinoma cells were expanded with various techniques for
multivariate analyses as described in Figure 1 flow diagram. Cox regressions were
computed for two variable models and models with an interaction term with gene
expression results from the candidate peptide/protein hormones and their
receptors. Least absolute shrinkage and selection operator (LASSO) was used to
fit a model with each of the 142 candidate genes at one time to determine the
relationship with prediction of risk of breast cancer recurrence.
In Chapter Two, univariate Cox regression evaluated the expression of each
gene’s influence on a breast cancer patient’s clinical outcome. A unique aspect to
this study is the ability to examine a peptide/protein hormone and their cognate
receptor/s as a combination and the manner in which these pairs of gene
expressions may play a role in predicting DFS and OS. A novelty of our study is
that we have discovered many primary breast carcinomas exhibit elevated levels
of expression of numerous genes for peptide/protein hormones and their receptors
which are known to regulate physiologic pathways. There is no biochemical
interaction between mRNAs but the proteins they eventually encode definitely
interact. The problem with measuring mRNA is that we cannot say with certainty
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that they will be coded into proteins. The correlation is there but the cell may have
mutations that fail to translate the mRNA into the protein. If we wanted to ensure
the levels of protein match the levels of mRNA then we would need to do qPCR or
other techniques that measure proteins in the cell. (Wu & Singh, 2012) Although
there is no biological interaction/association between each of the mRNA molecules
of a hormone and that of its receptor, a statistical interaction may be computed.
Methods and Materials
Multivariate Cox Regression
Two types of Cox models were employed to evaluate the relationships
between gene expression results for peptide/protein hormones and their cognate
receptors with clinical outcomes. The first computes a two variable model
(hormone + receptor) and the second model adds a third interaction term to the
model. The two variable model has the form ℎ(𝑡) = ℎ0 (𝑡) exp (𝛽1 𝑥1 + 𝛽2 𝑥2 ) and
the interaction model has the form ℎ(𝑡) = ℎ0 (𝑡) exp(𝛽1 𝑥1 + 𝛽2 𝑥2 + 𝛽3 𝑥1 𝑥2 ). (Klein
& Moeschberger, 1997) The expression of the hormone and receptor is
represented by x1 and x2, respectively. The baseline hazard at time t is represented
by h0(t) while the hazard at time t is represented by h(t). In a two-variable Cox
model, the beta coefficient for the hormone reflects the weight for which the
expression for the hormone’s gene has on the hazard function while controlling for
the expression of the receptor gene. Likewise, the beta coefficient for the receptor
gene expression reflects its weight on the hazard function while controlling for the
gene expression of the hormone. These models provide the HR for cancers
expressing a gene while accounting for the levels of the expression of its partner
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gene. In the interaction model, if the beta coefficient for the interaction term is
significant, then the gene expression results for the hormone and its receptor have
a strong statistical dependence on each other. Hazard ratios for the hormone and
receptor gene expression levels are conditioned on the level of its associated
partner. The exponentiation of 𝛽3 represents the excess hazard from the statistical
interaction of the gene expressions of the hormone and its cognate receptors.
Multivariate Cox regression analyses were extended to all of the subsets of
receptor status as discussed in Chapter Two Methods and Materials. Kaplan-Meier
(KM) plots were constructed along with each pair with and without regards to
ER/PR status to assess association with prediction of breast cancer recurrence.
KM plots were constructed with four categories: above the median gene
expression for both the hormone and receptor, below the median for both the
hormone and receptor and the two discordant combinations.
Least Absolute Shrinkage and Selection Operator
With such a large number of genes (e.g., 142), stepwise selection methods
to determine significant genes in a model are not feasible (Austin & Tu, 2004). An
increase in the standard error of coefficients due to the multicollinearity of gene
expression values may lead to type II errors – failure to reject a false hypothesis.
An alternative method, Least Absolute Shrinkage and Selection Operator
(LASSO), was used to evaluate each of the 142 candidate genes in primary breast
carcinoma cells of 247 patients in models for DFS and OS. LASSO penalizes the
size of ⃑β and removes genes whose coefficients are close to zero. The maximum
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likelihood estimates β̂ are derived by maximizing the penalized Cox log partial
likelihood with the form 𝑙 (𝛽) − ∑𝑝𝑗=1 𝜆|𝛽𝑗 |, where 𝑙 (𝛽) represents the standard log
Cox log partial likelihood and λ is the shrinkage parameter. Using 10-fold crossvalidation to minimizing the mean square error determined the optimal value for λ
(Andres et al., 2013). A larger λ corresponds to a larger penalty on the Cox log
partial likelihood and thus removes more variables from the model alleviated the
more predictive ability of overfitting a model. Further examination of the two clinical
outcomes (PFS & OS) with combinations of biomarker profiles were assessed as
well. The commands penalized and optL1 in the R package penalized were used
to perform an optimized L1 penalty, “LASSO”, for a Cox model. (J. Goeman,
Meijer, & Chaturvedi, 2014; J. J. Goeman, 2010)
Results
Multivariate Cox Regression with Interaction of PFS and OS without Regard to ER
and PR Status of the Cancer Biopsy
For interaction models, the sign of the beta coefficient for the interaction
term and its corresponding p-value are the most informative outputs from these
types of Cox regressions. A negative beta coefficient reflects an antagonistic effect
on the hazard, while a positive beta coefficient has a synergistic effect. For
instance in Table 11, HCRT (orexin) and HCRTR2 (hypocretin receptor 2)
exhibited a significant interaction term (adjusted p=0.23) for a false discovery rate
cutoff of p<0.3 for OS with a positive beta coefficient (β=1.53) that indicates there
is a significant increase in risk when expression levels of the two genes are
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considered together. HRs for the main effects (i.e., hormone or receptor) of these
Cox models are conditional HRs that depend upon the expression levels of the
other gene in the model and are not shown for the sake of brevity. Table 1 shows
the HR and 95% confidence interval for the HR of the interaction term and
represents the excess risk from a synergistic effect or reductive risk from an
antagonistic effect.
OS
Gene Symbol
HCRT & HCRTR2

β
1.53

HR
4.63

95% CI (HR)
(1.75,12.23)

adj. p
0.23

Table 11. Summary of the Interaction Term for Hormone and Receptor Gene Pairs
with Expression Levels Associated with OS without Regard to Receptor Status. As
described in Methods and Materials, expression levels of 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.

Multivariate Cox Regression with Interaction of PFS and OS with Regard to ER
and PR Status of the Cancer Biopsy
For ER+ cancers, two hormone-receptor pairs, INHA-ACVR2B and
GNRH2-GNRHR, exhibited significance when associated with OS (Table 12).
Interpretation of these interactions should be done with care. For example, inhibin
(INHA) and activin A receptor, type IIB (ACVR2B) has an antagonistic effect on the
overall hazard since the interaction beta coefficient (β 3) is negative. Yet, the beta
coefficients for the main effects (i.e., INHA (β1) and ACVR2B (β2)) are positive
(β1=0.52, β2=1.00), which can be interpreted as an increase in the expression level
of INHA or ACVR2B increases the risk of death (OS) at time t. In other words, the
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overall hazard is a convolution of the increased risk from the levels of INHA and
ACVR2B and the decreased risk from the statistical interaction of the two at these
levels. INHA-ACVR2B and GNRH2-GNRHR would be candidates for further study
to test signaling pathways for endocrine autonomy.
OS Interaction ER+
Gene Symbol
INHA & ACVR2B
GNRH2 & GNRHR

β
-1.62
9.99

HR
0.2
21907.54

95% CI (HR)
(0.08,0.51)
(26.77,17930991)

adj. p
0.09
0.20

Table 12. Summary of the Interaction Term for Hormone and Receptor Gene Pairs
with Expression Levels Associated with OS for 146 ER+ Breast Carcinomas. As
described in Methods and Materials, expression levels of 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.

For ER- cancers, Table 13 shows gene expression levels of five hormonereceptor pairs exhibiting significance for interaction for OS. The interaction term
for HCRT-HCRTR2 was significant for ER- breast cancer and also significant for
breast cancers without regard to receptor status. Interestingly, the hormonereceptor pairs significant for interaction in ER+ cancers reappeared with different
genes but from the same group. For example, INHA-ACVR2B was significant in
ER+ breast cancers and inhibin beta C (INHBC) and activin receptor type IB
(ACVR1B) was significant in ER- breast cancers. This is also similar for the
hormone gonadotrophin, which expressed type II significant for ER+ cancers and
type II significant for ER- cancers. Three out of the five pairs showing significance
for ER- cancers typically produce their hormone in the hypothalamus and regulate
a variety of other peptide/protein hormones. These three hormones, CRH, GNRH1
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and HCRT, should be examined more closely with the hormones they regulate to
verify any autocrine pathways in ER- breast cancers.
OS Interaction ERGene Symbol
IAPP & CALCR
INHBC & ACVR1B
CRH & CRHR1
GNRH1 & GNRHR
HCRT & HCRTR2

β
3.93
0.46
-1.9
2.77
1.5

HR
50.99
1.59
0.15
15.9
4.47

95% CI (HR)
(2.95,881.85)
(1.15,2.2)
(0.04,0.53)
(2.29,110.59)
(1.37,14.55)

adj. p
0.20
0.20
0.20
0.20
0.30

Table 13. Summary of the Interaction Term for Hormone and Receptor Gene Pairs
with Expression Levels Associated with OS for 101 ER- Breast Carcinomas. As
described in Methods and Materials, expression levels of 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.

For PR+ cancers, six pairs of hormone-receptor combinations showed
significance for OS (Table 14) Amylin (IAPP) and calcitonin receptor (CALCR)
exhibited the largest effect size for statistical interaction for PR+ cancers and
previously in ER- cancers. Because elevated levels of ER promote elevated levels
of PR, one would not expect genes that are expressed in ER- cancers to be
expressed in PR+ cancers. This anomaly should be investigated as a new finding
in order to rule out as simple randomness. POMC was identified for the first time
in these interaction models with its partner melanocortin 5 receptor (MC5R).
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OS Interaction PR+
Gene Symbol
IAPP & CALCR
RLN2 & RXFP1
CGA & TSHR
GHRH & GHRHR
EDN1 & EDNRA
POMC & MC5R

β
3.73
0.64
0.27
0.58
-1.1
2.78

HR
41.61
1.91
1.31
1.79
0.33
16.07

95% CI (HR)
(2.68,645.8)
(1.2,3.02)
(1.08,1.58)
(1.16,2.75)
(0.14,0.78)
(1.69,153.35)

adj. p
0.23
0.23
0.23
0.23
0.27
0.30

Table 14. Summary of the Interaction Term for Hormone and Receptor Gene Pairs
with Expression Levels Associated with OS for 151 PR+ Breast Carcinomas. As
described in Methods and Materials, expression levels of 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.

For LCM-procured breast carcinoma cells from PR- cancers, four hormone
and receptor pairs revealed significance for an association for OS (Table 15).
Orexin (HCRT) along with two of its cognate receptors, HCRTR1 and HCRTR2,
synergistically increased the risk for their hazard functions. An interesting result is
the significance of the pair cortistatin (CORT) and SSTR4 in ER- cancers. In ERcancers, POMC and PRL are overexpressed with relative gene expression means
of 0.38 and 0.24, respectively, while CORT and SSTR4 are under expressed with
relative gene expression means of -0.2 and -0.1, respectively. CORT has been
shown to have an inhibitory effect upon the production of POMC and PRL
(Córdoba-Chacón et al., 2011). If elevated gene expressions of POMC and/or PRL
in ER- cancer cells are in a signally pathway to cause progression or death from
the disease, then a therapeutic treatment for ER- cancers may be to find ways to
increase CORT and SSTR4 gene expression.
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OS Interaction PRGene Symbol
HCRT & HCRTR2
CRH & CRHR1
HCRT & HCRTR1
CORT & SSTR4

β
1.87
-1.79
2.31
1.14

HR
6.48
0.17
10.11
3.14

95% CI (HR)
(2.09,20.07)
(0.04,0.63)
(1.81,56.46)
(1.38,7.12)

adj. p
0.14
0.24
0.24
0.24

Table 15. Summary of the Interaction Term for Hormone and Receptor Gene Pairs
with Expression Levels Associated with OS for 96 PR- Breast Carcinomas. As described
in Methods and Materials, expression levels of 142 candidate genes were determined
using LCM-procured cells from 247 breast cancer biopsies.

For ER+/PR+ cancers, three pairs of hormone-receptor combinations
showed significance for estimating the relationship with PFS (Table 16). All three
pairs typically produce their hormones in the anterior pituitary gland. The hormonereceptor pair, pituitary adenylate cyclase-activating peptide (ADCYAP1) and
pituitary adenylate cyclase-activating peptide receptor (ADCYAP1R), indicated the
highest significance among these pituitary produced hormone pairs. ADCYAP1
has been tested as a methylation biomarker for cervical and endometrial cancer
(Jung et al., 2011; Wentzensen et al., 2014)
PFS Interaction ER+/PR+
Gene Symbol
ADCYAP1 & ADCYAP1R1

FSHB & FSHR
LHB & LHCGR

β
-0.65
24.77
9.58

HR
0.52
5.72E+10
14473

95% CI (HR)
(0.36,0.76)
(2153,1.52E+18)
(15,1.35E+7)

adj. p
0.08
0.23
0.23

Table 16. Summary of the Interaction Term for Hormone and Receptor Gene Pairs
with Expression Levels Associated with PFS for 118 ER+/PR+ Breast Carcinomas.
As described in Methods and Materials, expression levels of 142 candidate genes
were determined using LCM-procured cells from 247 breast cancer biopsies.
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When carcinomas expressing ER+/PR- status, six gene pairs were found
significant with three expressing synergistic and three expressing antagonistic
effects on the hazard function (Table 17). The effect sizes are large for these six
pairs but caution should be taken since the sample size is relatively small.
OS Interaction ER+/PRGene Symbol
SST & SSTR4
INHA & ACVR2B
RLN1 & RXFP1
EPO & EPOR
EDN1 & EDNRB
VIP & VIPR1

β
8.72
-7.11
5.67
14.1
-3.83
-3.61

HR
6096.72
0
289.4
1335702.39
0.02
0.03

95% CI (HR)
(11.48,3237235.64)
(0,0.13)
(3.81,22009.88)
(20,8.79E+10)
(0,0.44)
(0,0.39)

adj. p
0.24
0.24
0.24
0.24
0.24
0.24

Table 17. Summary of the Interaction Term for Hormone and Receptor Gene Pairs with
Expression Levels Associated with OS for 28 ER+/PR- Breast Carcinomas. As described in
Methods and Materials, expression levels of 142 candidate genes were determined
using LCM-procured cells from 247 breast cancer biopsies.

For ER-/PR+, two gene pairs were significant for an association with PFS
and 12 gene pairs were significant for an association with OS (Table 18). There
should be no surprise to find the pancreatic hormone amylin (IAPP) and its cognate
pair calcitonin receptor (CALCR) as the most significant pair for assessing the
relationship with both PFS and OS since its statistical interaction was found to be
the most significant separately for ER- and PR+ cancers. The heart hormone atrialnatriuretic peptide (NPPA) and each of its three receptors (NPR1, NPR2 and
NPR3) had a significant synergistic effect on the hazard for both predicting OS.
Yet, caution should be taken with these results due to the small sample size of 33
ER-/PR+ cancers.
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A. PFS Interaction ER-/PR+
Gene Symbol
IAPP & CALCR
NPPA & NPR3

β
7.49
3.58

HR
1781.76
35.86

95% CI (HR)
(15.68,202470.3)
(3.12,411.6)

adj. p
0.22
0.23

B. OS Interaction ER-/PR+
Gene Symbol
IAPP & CALCR
INHBA & ACVR1
NPPA & NPR3
INHBA & ACVR1B
INHBC & ACVR1B
INHBC & ACVR2B
INHBE & ACVR2A
RLN2 & RXFP1
CGA & TSHR
NPPA & NPR1
NPPA & NPR2
CORT & SSTR5

β
6.71
0.92
3.96
-0.76
1.09
0.98
-1.12
0.85
0.29
11.18
8.94
10.36

HR
818.18
2.52
52.38
0.47
2.96
2.66
0.33
2.33
1.34
71334.66
7617.82
31462.61

95% CI (HR)
(9.23,72540.58)
(1.35,4.7)
(3.41,804.52)
(0.24,0.89)
(1.27,6.92)
(1.23,5.74)
(0.13,0.81)
(1.14,4.76)
(1.04,1.72)
(3.98,1.27E+9)
(4.57,1.27E+7)
(3.73,2.65E+8)

adj. p
0.17
0.17
0.17
0.24
0.24
0.24
0.24
0.24
0.24
0.24
0.24
0.24

Table 18. Summary of the Interaction Term for Hormone and Receptor Gene Pairs with
Expression Levels Associated with either PFS (A) or OS (B) for 33 ER-/PR+ Breast
Carcinomas. As described in Methods and Materials, expression levels of 142
candidate genes were determined using LCM-procured cells from 247 breast cancer
biopsies.

For ER-/PR- cancers, two pairs of hormone-receptor genes showed
expression levels that exhibited significance for predicting OS (Table 19). HCRT
and HCRTR2 were found to be significant in both ER- and PR- cancers separately.
Surprisingly a new gene pair, arginine vasopressin (AVP) and cullin 5 (CUL5)
appeared with an antagonistic effect on its hazard. CUL5 has been shown to inhibit
cell proliferation (Burnatowska-Hledin et al., 2004; Van Dort et al., 2003).
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OS Interaction ER-/PRGene Symbol
HCRT & HCRTR2
AVP & CUL5

β
1.97
-1.44

HR
7.21
0.24

95% CI (HR)
(1.87,27.79)
(0.09,0.62)

adj. p
0.24
0.24

Table 19. Summary of the Interaction Term for Hormone and Receptor Gene Pairs with
Expression Levels Associated with OS for 68 ER-/PR- Breast Carcinomas. As described in
Methods and Materials, expression levels of 142 candidate genes were determined
using LCM-procured cells from 247 breast cancer biopsies.

Multivariate Cox Regression for the Hormone of PFS and OS without Regard to
ER and PR Status of the Cancer Biopsy
Two-variable models were employed to evaluate gene expression results
for the hormones while controlling for all the levels of relative gene expression for
their cognate receptors. In Table 20, the beta coefficient for the hormone term was
analyzed for PFS without regard to sex-hormone receptor status. Among the 20
gene pairs in the Table 20, the hormones with multiple receptors had multiple
appearances. Each of the hormones were significant for univariate analyses for
PFS with no significant effect of their betas when accounting for the statistical
presence of its receptor.
In Table 21, the beta coefficient for the hormone term was analyzed for OS
without regard to sex-hormone receptor status. The strength of the signal from
POMC regardless its cognate receptor dominated the significance for an
association for OS. All gene pairs significant for OS were significant for PFS
including secretin (SCT) with secretion receptor (SCRT) and pancreatic
polypeptide (PPY) with neuropeptide Y receptor (NPY4R).
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PFS Hormone
Two Gene Model
POMC + MC1R
POMC + MC2R
POMC + MC3R
POMC + MC4R
POMC + MC5R
SST + SSTR2
SST + SSTR5
SST + SSTR3
SST + SSTR4
PPY + NPY4R
CRH + CRHR1
REN + ATP6AP2
PRL + PRLR
SCT + SCTR
EDN1 + EDNRA
EDN1 + EDNRB
RLN1 + RXFP1
RLN1 + RXFP3
RLN2 + RXFP1
PTH + PTH2R

β for Hormone
0.54
0.56
0.54
0.54
0.51
0.56
0.55
0.51
0.54
0.96
0.54
0.6
0.32
0.57
0.39
0.4
-0.21
-0.2
-0.13
-1.26

HR
1.71
1.74
1.72
1.72
1.66
1.75
1.74
1.67
1.71
2.6
1.72
1.82
1.37
1.78
1.48
1.49
0.81
0.82
0.88
0.28

95% CI (HR)
(1.37,2.15)
(1.39,2.18)
(1.37,2.15)
(1.37,2.15)
(1.32,2.1)
(1.29,2.39)
(1.28,2.36)
(1.24,2.25)
(1.25,2.34)
(1.35,5.02)
(1.17,2.55)
(1.13,2.93)
(1.06,1.77)
(1.06,2.97)
(1.04,2.1)
(1.05,2.11)
(0.67,0.99)
(0.67,1)
(0.77,1)
(0.08,0.99)

adj. p
<0.001
<0.001
<0.001
<0.001
<0.001
0.007
0.007
0.01
0.01
0.05
0.07
0.13
0.15
0.21
0.21
0.21
0.28
0.30
0.30
0.30

Table 20. Summary of the Hormone Term from Two Variable Cox Models of Hormone
and Receptor Gene Pairs with Expression Levels Associated with PFS. As described in
Methods and Materials, expression levels of 142 candidate genes were determined
using LCM-procured cells from 247 breast cancer biopsies.
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OS Hormone
Two Gene Model
POMC + MC1R
POMC + MC2R
POMC + MC3R
POMC + MC4R
POMC + MC5R
SCT + SCTR
PPY + NPY4R

β for Hormone
0.52
0.53
0.52
0.52
0.48
0.77
0.88

HR
1.68
1.71
1.67
1.68
1.62
2.17
2.4

95% CI (HR)
(1.34,2.1)
(1.36,2.13)
(1.34,2.1)
(1.34,2.1)
(1.28,2.05)
(1.24,3.8)
(1.16,4.97)

adj. p
<0.001
<0.001
<0.001
<0.001
0.002
0.13
0.30

Table 21. Summary of the Hormone Term from Two Variable Cox Models of Hormone
and Receptor Gene Pairs with Expression Levels Associated with OS. As described in
Methods and Materials, expression levels of 142 candidate genes were determined
using LCM-procured cells from 247 breast cancer biopsies.

Multivariate Cox Regression for the Genes of Hormones of PFS and OS without
Regard to ER and PR Status of the Cancer Biopsy
Two-variable models were employed to evaluate gene expression results
for the receptors while controlling for all the levels of relative gene expression for
their cognate hormones. In Table 22, the beta coefficient for the receptor term was
analyzed for PFS without regard to sex-hormone receptor status. Receptors
appeared in nearly the same order they appeared in univariate analysis for PFS
with no significant effect on their betas when accounting for the statistical presence
of its hormone.
In Table 23, the beta coefficient for the receptor term was analyzed for OS
without regard to sex-hormone receptor status. Similar to PFS, the receptors
appeared in the same order as they did for significance in univariate Cox
regression with no effect seen with the statistical presence of its cognate hormone.
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This interpretation continues into the subtypes of ER/PR and for the sake of brevity
will not be shown here.
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PFS Receptor
Two Gene Model
CALCA + CALCR
IAPP + CALCR
IGF1 + IGF1R.clone
INS + IGF1R.clone
CORT + SSTR1
SST + SSTR3
INHA + ACVR2A
INHA + ACVR2B
INHBA + ACVR2A
INHBA + ACVR2B
INHBB + ACVR2A
INHBC + ACVR2A
INHBC + ACVR2B
INHBE + ACVR2A
INHBE + ACVR2B
AVP + AVPR2
CORT + SSTR3
VIP + VIPR1
NPY + NPY1R
INHBB + ACVR2B
ADCYAP1 + VIPR1
GHRL + GHSR
NPY + NPY6R
INHBB + ACVR1B
GH1 + GHR
AGT + RXFP3
INS + INSR.AL365454
INHBA + ACVR1
INHBA + ACVR1B
INHBC + ACVR1
INHBC + ACVR1B
INHBE + ACVR1B
INHA + ACVR1B
INHBE + ACVR1

β for Receptor
0.44
0.46
-0.17
-0.17
0.62
0.93
0.31
0.35
0.29
0.35
0.33
0.32
0.35
0.29
0.35
0.91
0.96
-0.28
-0.17
0.32
-0.25
-1.14
-1
0.27
0.43
1.23
-0.25
-0.27
0.26
-0.28
0.26
0.25
0.25
-0.27

HR
1.55
1.58
0.84
0.85
1.86
2.53
1.37
1.42
1.34
1.42
1.39
1.38
1.42
1.34
1.42
2.49
2.61
0.75
0.85
1.38
0.78
0.32
0.37
1.31
1.54
3.42
0.78
0.76
1.29
0.75
1.29
1.29
1.28
0.76

95% CI (HR)
(1.2,2)
(1.22,2.03)
(0.75,0.94)
(0.76,0.94)
(1.24,2.8)
(1.2,5.35)
(1.08,1.73)
(1.07,1.89)
(1.06,1.7)
(1.08,1.87)
(1.09,1.77)
(1.08,1.77)
(1.08,1.87)
(1.06,1.7)
(1.08,1.86)
(1.19,5.23)
(1.25,5.44)
(0.6,0.94)
(0.73,0.97)
(1.04,1.81)
(0.62,0.97)
(0.12,0.88)
(0.15,0.9)
(1.02,1.67)
(1.04,2.28)
(1.09,10.76)
(0.61,1)
(0.58,0.99)
(1.01,1.65)
(0.57,0.99)
(1.01,1.65)
(1.01,1.65)
(1,1.65)
(0.58,1)

adj. p
0.04
0.04
0.06
0.07
0.07
0.10
0.10
0.10
0.10
0.10
0.10
0.10
0.10
0.10
0.10
0.10
0.10
0.10
0.12
0.13
0.13
0.14
0.14
0.15
0.15
0.15
0.17
0.17
0.17
0.17
0.17
0.17
0.17
0.17

Table 22. Representative Summary of the Receptor Term from Two Variable Cox Models
of Hormone and Receptor Gene Pairs with Expression Levels Associated with PFS. As
described in Methods and Materials, expression levels of 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.
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OS Receptor
Two Gene Model
CALCA + CALCR
IAPP + CALCR
INS + IGF1R.clone
SST + SSTR3
IGF1 + IGF1R.clone
INHBB + ACVR2A
CORT + SSTR3
NPY + NPY6R
INHA + ACVR2A
INHBA + ACVR2A
INHBC + ACVR2A
INHBE + ACVR2A
VIP + VIPR1
NPY + NPY1R
INS + IGF1R
IGF1 + IGF1R
AGT + RXFP3
INHA + ACVR1
INHA + ACVR1B
INHA + ACVR2B
INHBA + ACVR1B
INHBA + ACVR2B
INHBB + ACVR1B
INHBC + ACVR1B
INHBC + ACVR2B
INHBE + ACVR2B
ADCYAP1 + VIPR1
ADCYAP1 + VIPR2
GHRL + GHSR
VIP + VIPR2
IAPP + RAMP2
INHBC + ACVR1
INHBA + ACVR1

β for Receptor
0.44
0.46
-0.17
1.11
-0.16
0.38
1.1
-1.4
0.35
0.35
0.36
0.34
-0.31
-0.2
-0.19
-0.18
1.29
-0.35
0.3
0.36
0.3
0.35
0.29
0.29
0.33
0.32
-0.27
-0.13
-1.35
-0.13
-0.18
-0.31
-0.29

HR
1.55
1.58
0.84
3.02
0.85
1.46
3.02
0.25
1.42
1.43
1.43
1.41
0.74
0.82
0.83
0.83
3.65
0.7
1.35
1.44
1.35
1.41
1.34
1.33
1.4
1.37
0.77
0.88
0.26
0.87
0.84
0.74
0.75

95% CI (HR)
(1.17,2.06)
(1.19,2.1)
(0.75,0.95)
(1.34,6.83)
(0.75,0.96)
(1.11,1.93)
(1.35,6.73)
(0.09,0.69)
(1.08,1.87)
(1.08,1.88)
(1.08,1.89)
(1.08,1.85)
(0.57,0.95)
(0.69,0.97)
(0.69,1)
(0.69,0.99)
(1.04,12.78)
(0.51,0.98)
(1.01,1.8)
(1.04,1.99)
(1.01,1.79)
(1.03,1.94)
(1.01,1.77)
(1,1.77)
(1.02,1.91)
(1,1.88)
(0.6,0.99)
(0.78,0.99)
(0.08,0.86)
(0.78,0.99)
(0.7,1)
(0.54,1)
(0.55,1.01)

adj. p
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.13
0.13
0.13
0.13
0.17
0.17
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.18
0.19
0.19
0.21

Table 23. Representative Summary of the Receptor Term from Two Variable Cox Models
of Hormone and Receptor Gene Pairs with Expression Levels Associated with OS. As
described in Methods and Materials, expression levels of 142 candidate genes were
determined using LCM-procured cells from 247 breast cancer biopsies.
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Kaplan-Meier Plots Discriminating Hormone-Receptor Pairs Whose Expression
Levels Predict Clinical Outcomes
With 115 possible pairs of genes for peptide/protein hormones and their
cognate receptors, 59 exhibited gene expression levels that were significant for
the non-parametric log-rank test for PFS and 41 were significant for the nonparametric log-rank test for OS without regard to receptor status (i.e., ER+, ER-,
PR+, PR- and ER/PR combinations). Figure 5 has a representative sample of the
most significant gene pairs from the log-rank test. Three examples are listed for
cancers with regard to receptor status and one example for ER+/PR+, ER-/PR-,
ER+, ER-, PR+ and PR-. There is a complexity to comparing these Kaplan-Meier
plots to our interaction models. The main effects of the hormone and receptor in
the interaction models are a stronger driver of the behavior of the four categories:
above/below the median expression for the hormone and above/below the median
expression for the receptor. Kaplan-Meier plots are different from our previous
analyses with univariate and multivariate Cox regression because the magnitude
of the relative gene expression isn’t considered in the analysis once cancers are
stratified into their respective groups. One aspect to consider when evaluating
these plots is the behavior of cancers that exhibit both elevated hormone and
receptor gene expression levels.
Without regard to ER/PR status, the PFS expressed in Kaplan-Meier plots
for SST & SSTR1 and SST & SSTR3 show a contrasting difference between
cancers exhibiting the worst prognosis that express mRNA levels of the hormone
and receptor above the median and cancers with the best prognosis that express
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the mRNA levels of hormone and receptor below the median (Figure 4). Three
plots discriminated cancers expressing mRNA above the median for the hormone
and receptor as the worst prognostic group, which included the OS without regard
to ER/PR status for POMC and MC5R, the OS for patients with ER+ cancers for
SST and SSTR2 and the PFS for patients with ER-/PR- cancers for ADCYAP1 and
VIPR2. For ER+/PR+ cancers, EDN1 & EDNRA was significant for OS for the
interaction term from multivariate Cox regression. EDN1 & EDNRA was also
significant for OS for KM plots with cancers expressing both the hormone and
receptor below the median resulting in the best prognosis. Gene expression results
shown in the Kaplan-Meier plots for AVP & AVPR2 (ER-, OS), MLN & MLNR (PR+,
PFS) and PTH & PTH2R (PR-, PFS), are representative of discordant pairs (i.e.,
above the median expression of the hormone gene and below the median
expression of the receptor gene) as the group of patients with the poorest
prognosis. Although the molecular basis for this predicted clinical behavior is
unknown currently, the gene expression patterns warrant further research to
determine if they may be useful in predicting clinical outcomes.
Multivariable Gene Expression Model fitted using the LASSO
The use of regularization techniques such as LASSO allowed us to evaluate
gene expression levels of all 142 gene candidates to a model by penalizing the
number of parameters in the model. The analyses were performed for predicting
either PFS or OS without regard to either ER or PR receptor status, as well as in
relationship to the four different combinations of ER/PR. Using the loss function to
decide which model is the best, only three groups showed the minimal loss function
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not equal to all zeroes for beta coefficients. In other words, all but three models
exhibited their best fitted models having coefficients with all zeroes, which
translates to having no significant variables associated with PFS and OS when a
penalty is put on the size of the beta coefficients.
The LASSO fitted and cross-validated model for predicting breast cancer
outcome expressing ER+/PR+ status for predicting OS was composed of
expression levels of seven hormone genes (IGF1, INHBB, GNRH2, PENK,
CALCA, GAL and PTMS) and those for nine receptor genes (SSTR2, SSTR3,
SSTR4, PRLHR, EPOR, PRLR, CUL5, NPY2R and NPY5R) (Table 24). Strikingly,
expression results of each of the eight genes showing statistical significance in
univariate Cox regression analyses for predicting OS of ER+/PR+ cancers
reappeared in the model derived from LASSO. The LASSO derived model of gene
expression results for predicting PFS of ER-/PR- cancers was composed of five
hormone genes (AGT, POMC, GH1, PRL and PTH) and five receptor genes
(CALR, SSTR1, AGTRAP, AVPR1A and AVPR2). Expression levels of these ten
genes were all significant for predicting PFS of ER-/PR- cancers from univariate
analyses. The LASSO derived model for prediction of PFS of ER- breast cancers
was composed of four hormone genes (POMC, GH1, LHB and SCT) and two
receptor genes (CALCR and AVPR1A). Expression levels of these six genes were
all significant for assessing PFS of ER- breast cancers using univariate analyses.
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Figure 5. Representative Kaplan-Meier Plots Comparing Above and Below the Median
Relative Gene Expression for Peptide/Protein Hormones and Their Cognate Receptors.
Cancers with above the median expression for the hormone and the receptor have the
worst prognosis (A (n=247), B (n=247), C (n=247), E (n=68), F (n=146)). ER+/PR+ cancers
with below the median expression for both the hormone and receptor have the best
prognosis. (D (n=118)) Cancers with below the median expression for the hormone and
above the median expression for the receptor have the worst prognosis (G (n=101), I
(n=96)). Cancers with above the median expression for the hormone and below the
median expression for the receptor have the worst prognosis (H (n=151)).
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A. OS ER+/PR+
Gene Symbol
SSTR2
SSTR3
SSTR4
IGF1
INHBB
GNRH2
PRLHR
PENK
EPOR
PRLR
CUL5
CALCA
GAL
NPY2R
NPY5R
PTMS

β
2.01
1.04
0.17
-0.31
-0.59
0.39
-0.78
-0.06
0.12
0.42
-0.41
1.27
0.08
0.34
-0.03
0.19

B. PFS ER-/PRGene Symbol
CALCR
SSTR1
AGT
AGTRAP
POMC
GH1
PRL
AVPR1A
AVPR2
PTH

β
0.17
0.03
0.14
-0.09
0.31
-0.38
0.10
0.12
0.21
-0.07

C. PFS ERGene Symbol
CALCR
POMC
GH1
LHB
SCT
AVPR1A

β
0.35
0.31
-0.40
0.05
0.13
0.23

Table 24. Significant Genes and Corresponding Beta Coefficients for LASSO Performed
on 142 Peptide/Protein Hormones and Their Cognate Receptors With and Without
Receptor Status of Breast Carcinomas. ER+/PR+ cancers for OS (A), ER-/PR- cancers for
PFS (B) and ER- cancers for PFS (C) were significant models from LASSO with a
maximized likelihood from an L1 penalty and cross-validation.

Discussion
The expansion of our analysis with multivariate techniques intended to
exhaust all the relationships hormones and receptors may have on each other.
Two variable models proved to be no better at predicting PFS and OS than their
respective univariate models. However, the interaction models gave us a myriad
of questions to be answered, which is exactly what an exploratory based study
should do.
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Interaction models allowed us to explore the idea of endocrine autonomy
where a cancer cell produces hormone proteins that bind to its own receptor
proteins. This self-promoting loop could be associated with signaling pathways for
proliferation. The idea that cancer cells have autonomous mechanisms to promote
proliferation is not new (Hanahan & Weinberg, 2000). In addition, we know of a
few peptide proteins which have been researched as biomarkers for early cancer
detection (Assiri, Kamel, & Hassanien, 2015; Bae, Schaab, & Kratzsch, 2015). Yet
to the best of our knowledge no one as looked at these peptide/protein hormones
and their cognate receptors collectively.
What we have revealed with the novel findings from significant gene pairs
for interaction are potential gene pairs to be used in a molecular model to predict
cancer prognosis or potential targets for therapy. Throughout our exhaustive
search through related literature, we found no studies that employed the use of
statistical interaction to develop their molecular signatures to predict cancer
behavior. For future studies we would like to investigate combinations of these
significant genes for interaction to develop a unique molecular signature. Hormone
therapy treatment with tamoxifen blocks the estrogen receptor site, thus disrupting
the function of the receptor signaling inside the cell. If further investigation reveals
a pathway for proliferation through one of our many hormone-receptor pairs, then
specific targets could be developed to block those receptor sites.
The Kaplan-Meier plots offered us the best visual understanding of the
relationship between hormones and their cognate receptors. The distinction drawn
from cancers expressing high levels of hormones and receptor genes and those
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expressing low levels of hormone and receptor genes suggests a strong doseresponse for predicting PFS and OS (i.e., (A) SST and SSTR3 and (B) SST and
SSTR1 in Figure 5). Significant Kaplan-Meier plots with a single group exhibiting
a worse prognosis spawn exploratory ideas such as why do patients with cancers
expressing high levels of the hormone motilin (MLN) and low levels of its cognate
receptor MLNR have a significantly worse prognosis compared to the other three
groups (Figure 5 (H)). The best way to embark on an investigation of one of these
anomalies is to culminate univariate and multivariate Cox regressions, ER/PR
boxplots and Kaplan-Meier plots for the hormone and receptor. Thus, these results
serve as a platform for further investigation.
LASSO was performed on all 142 peptide/protein hormones and their
cognate receptors to evaluate which genes were being expressed with the
strongest signals for predict PFS and OS. The only non-zero models materialized
from ER/PR subtypes. This suggests that the role of the sex hormones play a
larger role in the behavior of peptide/protein hormones and receptors in predicting
PFS and OS than trying to predict PFS and OS without considering the ER/PR
receptor status. Receptor status is essential to determining the type of treatment
a patient receives. Further examination of our findings may provide better
prognosis for breast cancer patients across multiple biomarkers especially with the
molecular signatures developed in Chapter IV.
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CHAPTER IV
META-ANALYSIS AND MOLECULAR SIGNATURES
To strengthen our findings of specific genes whose expression predicts
clinical behavior of breast cancer, we extended our analyses by examining our
results with those reported in several public databases. The unique nature of the
HRL dataset, having been developed using RNA extracted from Laser Capture
Micro-dissected breast carcinoma cells, made direct comparisons to results of
each of the four public databases examined difficult since none of them used LCM
techniques in their studies. Therefore, it was reasoned that the meta-analysis
would be conducted using various approaches of combining the HRL dataset with
the public databases to determine the relationships of expression of genes for the
142 peptide/protein hormone and their cognate receptors related to clinical
outcomes of breast carcinoma patients (Figure 1 Flow Diagram).
Methods and Material
Public Databases
One of the widely accepted practices is to externally validate the significant
findings of our study using public datasets. Four public databases, TRANSBIG,
VDX, MAINZ and UNT, were chosen based on the strength of their studies and
their accessibility through Gene Omnibus Expression (GEO). Gene
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expression values and clinical measurements were downloaded using the
Bioconductor

(version

3.2)

packages

‘breastCancerTRANSBIG’,

‘breastCancerVDX’, ‘breastCancerMAINZ’ and ‘breastCancerUNT’. Microarray
data of relative gene expression levels determined with the AffymetrixU133a
GeneChip were reported by TRANSBIG, VDX, MAINZ and UNT. TRANSBIG
contained results from 198 lymph-node negative patients treated at five different
centers. (Buyse et al., 2006) (Desmedt et al., 2007) VDX reported the relative gene
expression results from 286 lymph-node negative patients with primary breast
cancer. (Wang et al., 2005) The MAINZ database contained results from 200-node
negative patients. (Schmidt et al., 2008) while UNT reported gene expression
levels of 189 lymph-node negative patients. (Sotiriou et al., 2006) Each of the four
public databases employed in these investigations contained the levels of estrogen
receptor expressed in each cancer biopsy.
Prior to performing meta-analysis, the relative expression levels of each of
the 142 candidate genes were normalized to a mean of zero and standard
deviation of one within each of the five datasets. The relative gene expression
results of the HRL database and those of the four public databases, in various
combinations, were concatenated into individual datasets. No weight was given to
any dataset nor to any subset of patients based on their characteristics (e.g., ER
status of the cancer). Using each of the combined datasets, univariate Cox
regression and multivariate Cox regression analyses were performed with gene
expression results of each of the 142 candidate genes using only the clinical
outcome PFS/RFS and the status of the biomarker, ER.
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Molecular Signatures and Multivariable Cox Model
The field of 142 candidate genes was constricted to a smaller specialized
group by a predefined criterion. In order for a gene to meet the criterion it must be
significant (p < 0.05) for univariate Cox regression in the HRL data analysis and at
least one other public database. This technique gives a higher preference for the
HRL dataset, which is the only database to use LCM on its tissue biopsies.
These genes were selected as the special candidates for a molecular
signature to be modeled with training and test sets using the meta-analyses
dataset. Initially, the patients were placed into subsets based on their ER status
since ER status is a strong predictor of clinical outcome. Patients were randomly
selected into a 70% training set and the other 30% of patients were placed in a
test set. Equal proportions of ER+ and ER- patients were selected to reflect the
same proportion in the entire population. This randomization was independently
repeated 1000 times.
Each training set was evaluated using Least Absolute Shrinkage and
Selection Operator (LASSO) with an L1 penalty determined by the optL1 command
in the penalized package. An L1 penalty shrinks the beta coefficients of nonsignificant genes to zero. The genes in each model were tallied after 1000
iterations. The number of gene occurrences in the training models was then
compared to the maximum gene occurrence in permuted data sets. The permuted
sets were constructed by randomly reordering the patient’s clinical outcomes
against their gene expression values. This approach established a baseline for the
noise in the data as well as identified the genes with the strongest signals. Any of
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the genes within the training set that contain a higher frequency than the maximum
frequency in the permuted set were considered to be significant. (S. A. Andres et
al., 2015)
Linear predictors were determined with the training set models and applied
to the remaining 30% (test sets). A linear predictor is constructed for each patient
by the summation of the relative gene expressions for each gene in the model
multiplied by each gene’s beta coefficient. The linear predictors were segregated
into above/below the median subsets. Kaplan-Meier plots were constructed for the
median splits using all models that had predictors in them. In order to visually
compare these plots an alternative Kaplan-Meier plot was constructed which
permuted the clinical outcomes (progression free survival, recurrence) against
their corresponding linear predictors. These alternative plots should have no
recognizable pattern between the median and tertiary split subsets. The
distributions of the p-values from the non-zero Cox models, median splits, and
tertiary subsets are shown in boxplots.
In order to externally validate the genes in our molecular signatures (MS),
the four public databases were divided into 1000 training (70%) and test (30%)
sets. The beta coefficients determined by Cox regression with the genes in each
of the molecular signatures were applied to their corresponding test set. These
linear predictors were evaluated against the clinical outcomes of the test set using
the concordance index (C-index). Boxplots were employed on the 1000 C-indices
to illustrate their distributions. The R command rcorrcens in R package Hmisc
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calculated the C-index for each linear predictor and set of clinical outcomes (RFS
for TRANSBIG and UNT and DMFS for VDX and MAINZ).
Results
Meta-analysis of HRL and Four Public Databases
Univariate Cox regression performed on 1126 breast cancer biopsies (HRL
and four public databases combined) for each of the 142 candidate genes resulted
in 12 genes exhibiting unadjusted p-values < 0.07. After p-values were adjusted
for multiple comparisons using the Benjamin-Hochberg method, no genes met the
0.3 discovery threshold. Two limitations of this analysis are the clinical outcome
being measured by MAINZ and VDX ignore local metastasis as an event and none
of the public databases utilized LCM to avoid the convolution of surrounding noncancerous tissues in their analyses. Despite limitations and loss of significance
after controlling for the false discovery rate, RLN2, RLN1, VIPR1 and ACVR1B
appear later in our 14-gene molecular signature for cancers without regard to
receptor status.
Univariate Cox regression performed on 737 ER+ breast cancer biopsies
for each of the 142 candidate genes resulted in eight genes exhibiting an
association with PFS/DMFS and unadjusted p-values less than 0.04. Univariate
Cox regression performed on 378 ER- breast cancer biopsies for each of the 142
candidate genes resulted in 13 genes exhibiting an association with PFS/DMFS
and unadjusted p-values less than 0.07. After adjusting p-values for multiple
comparisons, the expression of genes in neither ER+ nor ER- cancers exhibited
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Gene Symbol
RLN2
GHR
FSHB
VIPR2
ADCYAP1
VIPR1
TRH
RLN1
SSTR3
ACVR1B
TMSB10
THPO

β
-0.14
0.12
-0.12
-0.11
0.1
-0.1
-0.1
-0.09
0.09
0.1
0.09
0.09

HR
0.87
1.13
0.89
0.89
1.11
0.91
0.9
0.91
1.1
1.1
1.1
1.1

95% CI (HR)
(0.78,0.96)
(1.03,1.25)
(0.81,0.98)
(0.81,0.99)
(1,1.23)
(0.83,1)
(0.81,1)
(0.83,1)
(1,1.21)
(1,1.22)
(1,1.21)
(1,1.21)

p
0.01
0.01
0.02
0.02
0.04
0.05
0.06
0.06
0.06
0.06
0.06
0.06

adj. p
0.69
0.69
0.69
0.69
0.69
0.69
0.69
0.69
0.69
0.69
0.69
0.69

Table 25. Summary of the Genes from Meta-analysis without Regard to Receptor Status
(n=1126) with Expression Levels Associated with PFS/DMFS. As described in Methods
and Materials, expression levels of 142 candidate genes were determined using LCMprocured cells from 247 breast cancer biopsies.

adjusted p-values less than the 0.3 threshold. The unadjusted univariate
associated gene, GRP, for ER+ cancers appears in the 3-gene molecular
signature for ER+ breast cancers while the unadjusted univariate associated
genes, IGF1 and POMC, for ER- cancers appear in the 9-gene molecular signature
for ER- breast cancers (Figure 7).
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A. PFS/DMFS ER+
Gene Symbol
RLN2
THPO
PRLR
SST
C19orf80
ACVR1B
GRP
ATP6AP2

β
-0.19
0.15
0.15
0.15
-0.15
0.14
-0.14
0.15

HR
0.82
1.16
1.17
1.16
0.86
1.15
0.87
1.16

95% CI (HR)
(0.72,0.94)
(1.03,1.31)
(1.02,1.33)
(1.02,1.32)
(0.76,0.98)
(1.02,1.31)
(0.77,0.98)
(1.02,1.33)

p
0.01
0.01
0.02
0.02
0.02
0.03
0.03
0.03

adj. p
0.45
0.45
0.45
0.45
0.45
0.45
0.45
0.45

B. PFS/DMFS ERGene Symbol
IGF1
PTMS
AVPR2
GHR
POMC
TSHB
VIPR2
GALR3
LEPR
RAMP2
C19orf80
INSR
CAP2

β
0.22
0.22
0.18
0.16
0.15
-0.19
-0.17
-0.17
0.16
0.15
0.15
0.14
-0.15

HR
1.25
1.25
1.2
1.18
1.16
0.83
0.84
0.84
1.17
1.16
1.16
1.14
0.86

95% CI (HR)
(1.06,1.46)
(1.05,1.49)
(1.02,1.4)
(1.02,1.37)
(1.01,1.33)
(0.7,0.99)
(0.71,0.99)
(0.71,0.99)
(1,1.37)
(1,1.36)
(0.99,1.36)
(0.99,1.32)
(0.74,1.01)

p
0.01
0.01
0.02
0.03
0.03
0.04
0.04
0.04
0.05
0.05
0.06
0.06
0.06

adj. p
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.63

Table 26. Summary of the Meta-analysis for (A) ER+ (n=737) and (B) ER- (n=378) Breast
Cancers with Expression Levels Associated with PFS/DMFS. As described in Methods
and Materials, expression levels of 142 candidate genes were determined using LCMprocured cells from 247 breast cancer biopsies.
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Kaplan-Meier Plots Demonstrating Results from Meta-Analysis
The Kaplan-Meier plots in Figure 6 compare the difference between breast
cancers reported in the public databases and in the HRL database expressing a
gene above and below the median. The three most significant genes are shown
for the 1126 cancers without regard to receptor status, 737 ER+ cancers and 378
ER- cancers (11 cancers had missing data on ER status). For breast cancers
without regard to receptor status, patients with cancers that expressed ADCYAP1
and SST above the median and VIPR2 below the median had the worst prognosis.
Noteworthy, SST and VIPR2 appear in the 14-gene molecular signature (Figure
7). Patients with ER+ breast cancers expressing SST and SSTR2 above the
median and RAMP2 below the median tend to have a shorter time for a recurrence
of cancer. Interestingly, SSTR2 also appears in the 3 –gene molecular signature.
Patients with ER- breast cancers expressing C19orf80 above the median and TRH
and FSHB below the median exhibited the worst prognosis.
Gene Signatures Predicting Clinical Behavior of Breast Carcinomas
Significant genes from univariate Cox regression, either PFS or OS, were
analyzed for their ability to predict risk of breast cancer recurrence as a set with
1000 LASSO training/test sets. The genes that occurred in more models than in
the permuted set, which serves as the null distribution, are considered gene
signature candidates until externally compared with results in public databases, as
described in Methods and Materials. A 14-gene subset was identified as a
candidate molecular signature for predicting clinical outcome without regard to the
sex hormone receptor status of the breast cancer biopsies (Figure 7). When sex67

hormone receptor status was considered, a three-gene signature composed of
NPY1R, SSTR2 and GRP was deciphered for ER+ breast cancer biopsies and a
candidate 9-gene signature was identified for ER- breast cancer biopsies.
The 14-gene signature was composed of expression patterns for eight
receptor genes and six hormone ligand genes. Of these 14 genes, only NPY1R
was also identified in the 3-gene signature in ER+ breast cancers (Figure 7).
Interestingly, three of the genes, POMC, CALCR and PRL, of the signature
deciphered without regard for ER status were also found in the 9-gene signature
identified in ER- breast cancers. Surprisingly, in contrast to the composition of the
14-gene signature, only two of the 9 genes of the molecular signature associated
with ER- breast cancer direct the synthesis of hormone receptors. No genes
reflecting peptide/protein hormone-receptor pairs were detected in the 14-gene
signature nor in the 3-gene signature. It is noteworthy, that the gene for the
hormone prolactin (PRL), which plays a central role in breast physiology, and
prolactin’s cognate receptor PRLR appeared in the 9-gene signature for ERbiopsies.
Concordance indices evaluated the predictive ability of the genes in each
of the three molecular signatures on each of the four public databases. Figure 8
summarizes the distribution of the C-indices determined by 1000 training and test
sets. The 9-gene MS performed better than the 14-gene and 3-gene MS in VDX,
UNT and MAINZ and as well as the 3-gene model in TRANSBIG. The median Cindex for the 9-gene model was greater than 0.6 for two public databases, MAINZ
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and UNT. Excitingly, the best predictive MS is in the 9-gene model for ER- cancers,
since patients with ER- cancers have very limited treatment options.
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Figure 6. Representative Kaplan-Meier Plots Comparing Above and Below the Median Relative
Gene Expression of 142 Peptide/Protein Hormones or Their Cognate Receptors with and without
Regard to ER Status for PFS from the Meta-analysis. Without regard to ER status, 1126 breast
carcinomas expressing ADCYAP1 (A) and SST (C) above the median and VIPR2 (B) below the
median had the worst prognosis. 737 ER+ breast carcinomas expressing RAMP2 (D) below the
median and SST (E) and SSTR2 (F) above the median had the worst prognosis. 378 ER- breast
carcinomas expressing TRH (G) and FSHB (H) below the median and C19orf80 (I) above the
median had the worst prognosis.
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Figure 7. Composition of Molecular Signatures Derived Showing Genes Common
to Each
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Figure 8. Summary of 1000 C-indices of Each of the Three Molecular Signatures on Each
of the Four Public Databases, (A) VDX, (B) TRANSBIG, (C) UNT and (D) MAINZ. The 14Gene MS was applied to cancers without regard to receptor status. The 3-Gene MS and
9-Gene MS was applied to ER+ and ER- cancers, respectively. Validation of the genes in
the three MS was performed by dividing public databases into 70% training and 30%
test sets.
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Discussion
As expressed earlier, our overarching goal is to determine the relationships
of the expression of the genes for each of the peptide/protein hormones and that
of their cognate receptors with clinical outcomes of breast cancer patients. Our
hypothesis is that expression profiles of subsets of these genes for regulatory
molecules may be used to predict risk of breast carcinoma recurrence in patients
with primary disease. It appears that our approach described in Figure 1 is original
considering the following resources: 1) only de-identified breast cancer tissues
were processed by LCM for microarray, 2) gene expression levels reflected only
mRNA of specific cell types, 3) 22,000 genes were determined in 247 primary
breast carcinomas in a standardized fashion and 4) data were complemented by
quantitative results of protein biomarker levels (ER, PR and HER-2). These
unparalleled properties of each specimen were accompanied by clinical follow-up
and patient outcome. A multitude of statistical analyses such as univariate and
multivariate Cox regressions, Kaplan-Meier plots, boxplots and LASSO were
utilized to predict a patient’s clinical outcome.
Recall from Chapter II the importance POMC, GH1 and CALCR contributed
to predicting PFS and OS for univariate Cox regression and Kaplan-Meier plots for
ER- subtypes of breast carcinomas. SST and its cognate receptors diverge
expression towards cancers exuding estrogen receptor proteins (ER+). POMC is
the standout gene from univariate Cox regression with and without regard to
receptor status while GH1 in ER- cancers displayed an exceptional differentiation
between cancers expressing the gene at high and low levels. POMC has appeared
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in many studies showing an association with a variety of diseases such as obesity
and cancer (Clark, 2015; Mountjoy, 2015). Other studies have shown
polymorphisms of GH1 to have a protective influence on breast cancer risk
(Wagner et al., 2006). Although we did not examine polymorphism, we did
independently show that elevated levels GH1 in breast carcinomas have a
protective effect. These findings warrant further the investigation of these two
genes with the HRL’s Next Generation Sequencing (NGS) database.
Chapter III explored a myriad of multivariate predictors for progression of
disease and survivorship of patients with primary breast cancers. A number of
hormone-receptors exhibited a significant statistical interaction such as the pairs
HCRT-HCRTR2 in ER- and PR- cancers, IAPP-CALCR in ER- cancers and FSHBFSHR in ER+/PR+ cancers. Two variable models did not distinguish any better
predictors for PFS and OS than univariate Cox regression results contributed.
LASSO revealed the prominence of the role that sex hormone status performs in
predicting PFS and OS for peptide/protein hormones and their receptors. The
significant LASSO results of 16 genes for ER+/PR+ cancers, 10 genes for ER-/PRcancers and 6 genes for ER- will be externally validated with the public databases
as alternative molecular signatures in future studies.
We learned from Chapter IV that the significance of many genes in the
meta-analysis evaporated when adjusted for multiple comparison were calculated.
This loss in the number of significant genes happened throughout the study. The
challenge of exploring the relative expression levels of 142 genes is not just the
volume of work to be organized but discretizing statistical significance from the
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inherent noise of highly correlated data found in microarray. Our original answer
to the question of how to validate our discoveries since most of them could not
overcome the loss of significance from adjusting for a false discovery rate was the
use of public databases. The challenge was the lack of public databases that used
LCM to ensure only cancer cells were being evaluated and the uncertainty of their
consistency used in specimen collection and lab techniques.
Despite these challenges, our 9-gene molecular signature for ER- cancers
performed better than the 14 gene and 3-gene MS in predicting the PFS/DMFS in
all four public databases. The median concordance index of two public databases
was over 60%. In summary, the resources and approach clearly support the
integrity of the molecular signatures primary breast carcinoma to predict risk of
recurrence. Additional steps in the clinical validation of these signatures may
include the implementation of a clinical trial whereby the molecular signatures are
used as biomarkers with and without regard to sex hormone receptor status of the
breast carcinoma biopsy.
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